Document:

Exhibit
10.1

 

JOINT
VENTURE AGREEMENT

 

THIS
JOINT VENTURE AGREEMENT (this “Agreement”) is made as of June 28, 2021, by and between INVO Centers, LLC (“INVO”),
a Delaware limited liability company, and Bloom Fertility, LLC, a Georgia limited liability company (“Provider”).
INVO and Provider may be referred to individually as a “Party” and together as the “Parties.”

 

RECITALS

 

1.
Provider is a medical practice in the State of Georgia that employs physicians who, by education, training and experience, are qualified
to provide fertility and reproductive medical services;

 

2.
INVO is an Affiliate of INVO Bioscience, Inc., a Nevada corporation (“INVO Bioscience”), a medical device company
focused on creating simplified, lower cost treatments for patients diagnosed with infertility using a patented medical device (the “INVOcell”)
and an in vivo method of vaginal incubation (the “INVO Procedure”), and, through its relationship with INVO
Bioscience, INVO has certain rights to use the INVOcell, INVO Procedure, and related treatments using artificial reproductive technologies
pioneered or created by INVO Bioscience (collectively, the “INVO Technologies”);

 

3.
In connection with the definitive transaction agreements to be executed pursuant to this Agreement, INVO and Provider have determined
that it is in their mutual best interest to organize and own in a joint venture, Bloom INVO LLC, a Delaware limited liability company
(the “Company”), pursuant to which:

 

a)
The Company will, subject to the equity and debt arrangements described herein, assist Provider in establishing a fertility center that
will offer the INVO Technologies, along with related procedures and such other technologies or procedures that may be agreed to by the
Parties from time to time (the “INVO Clinic”);

 

b)
INVO will make available to the Company the INVO Technologies, and, subject to INVO’s existing third-party distribution arrangements,
be the exclusive provider to Company of the INVOcell and other medical devices and supplies for use at the INVO Clinic;

 

c)
The Company shall provide comprehensive management services to the INVO Clinic, including full administrative, billing and collection,
business, consulting, financial, marketing, staffing, and other support services necessary for its operations, including but not limited
to clinical laboratory services, pursuant to an exclusive, long-term management services agreement (the “Management Services
Agreement”); and

 

d)
The Provider will provide all professional services required for the operation of the INVO Clinic; and

 

4.
In furtherance of the foregoing, the Parties desire to enter into this Agreement to establish the rights and obligations of each Party
with respect to the INVO Clinic.

  

AGREEMENT

 

NOW
THEREFORE, in consideration of the mutual promises herein and other good and valuable consideration, and incorporating the foregoing
recitals, the Parties agree as follows:

 

    	-1-

    	 

    

 

ARTICLE
1.

CONTRIBUTIONS TO THE COMPANY; NO ASSUMPTION OF LIABILITIES

 

Contributions
to the Company will be made by the Parties at Closing or thereafter in accordance with the LLC Agreement of the Company, substantially
in the form attached hereto as Exhibit A. The Company shall not assume or be responsible to perform, pay or discharge, and shall
have no liability for, and each Party shall remain liable for any obligations, liabilities and commitments of each such Party, as applicable,
of any kind or nature, known or unknown, fixed or contingent, including all costs and expenses of the Parties incident to this Agreement,
including but not limited to any Taxes applicable to the transactions contemplated hereby (collectively, the “Excluded Liabilities”).

 

ARTICLE
2.

COMPANY OWNERSHIP AND MANAGEMENT

 

2.1
Initial Unit Issuance; Vesting. The Company shall initially have Two Thousand (2,000) Units authorized for issuance to the Parties.
Effective as of the Closing, (a) in exchange for INVO’s initial Capital Contribution (the “INVO Contribution”),
the Company shall issue Eight Hundred (800) of its Units to INVO, subject to the terms and conditions of Section 4.3(a)(i) of the LLC
Agreement; and (b) in exchange for Provider’s satisfaction of the Provider Requirements, the Company shall issue One Thousand Two
Hundred (1,200) of its Units to Provider, subject to the terms and conditions of Section 4.3(a)(ii) of the LLC Agreement.

 

2.2
Management of Company. The Company will be managed pursuant to the terms set forth in the LLC Agreement. The Parties shall take
such actions as may be required to ensure that (i) the number of Managers constituting the Board of Managers of the Company (the “Board”)
is at all times equal to five (5) Managers, and (ii) the presence of at least three (3) Managers (one of whom is appointed by INVO) is
required to constitute a quorum of the Board. The Board may act by majority vote in accordance with the terms of the LLC Agreement. Provider
shall have the right to appoint three (3) Managers and INVO shall have the right to appoint two (2) Managers to serve on the Company’s
Board, and the initial Managers will be set forth in the LLC Agreement. 

 

2.3
Distributions of Distributable Cash. As further described in the LLC Agreement, each year, any excess positive operating cash
flow of the Company, net of reasonable reserves for operating expenses, Taxes, and such other purposes as determined by the Board (“Net
Available Distributions”), will be distributed to Parties on an annual basis in an amount equal to sixty percent (60%) to Provider,
and forty percent (40%) to INVO (the “Equity Distributions”); provided, however, until the Loans have
been repaid in full, fifty percent (50%) of any such Net Available Distributions will be used by Company to repay the Build-Out Loan
(including both interest and principal, when payable under the terms of the Build-Out Loan) and before distributing the remainder of
Net Available Distributions to the Parties based on their respective Equity Distributions; provided, further, in the event
the Build-Out Loan has not been repaid in full when due pursuant to its terms, then one-hundred percent (100%) of any such Net Available
Distributions will be used by Company to repay the Build-Out Loan (including both interest and principal, when payable under the terms
of the Build-Out Loan) and before distributing the remainder of Net Available Distributions to the Parties based on their respective
Equity Distributions.

 

    	-2-

    	 

    

 

ARTICLE
3.

CLOSING

 

The
consummation of the transactions contemplated by this Agreement (the “Closing”) shall occur at the offices of Sheppard,
Mullin, Richter and Hampton, LLP, 30 Rockefeller Plaza, New York, NY 10112-0015 on the first (1st) business day after the conditions
set forth in ARTICLE 6 have been satisfied or waived, or at such other place and time as shall be agreed upon by the Parties.
The date on which the Closing is actually held is referred to herein as the “Closing Date”. Unless otherwise agreed
in writing by the Parties at Closing, the Closing shall be deemed to have occurred and the transactions contemplated by this Agreement
shall be deemed effective for financial and accounting purposes as of 12:01 a.m., Eastern Time on the Closing Date. At the Closing, each
Party shall deliver to the other Party those items and documents described in ARTICLE 6.

 

ARTICLE
4.

COVENANTS OF THE PARTIES

 

4.1
Management Services Agreement. At Closing, the Company and Provider shall enter into the Management Services Agreement, substantially
in the form attached hereto as Exhibit B, pursuant to which the Company shall provide day-to-day management of operations of Provider
in accordance with the terms and conditions set forth therein.

 

4.2
Loan to Company INVO will, at the Closing, commit to issue debt to the Company in an amount up to Six Hundred Thousand Dollars
($600,000) for construction or improvements related to the INVO Clinic (the “Build-Out Loan”) upon terms and conditions
mutually agreeable to INVO and Company. Any amount payable to INVO by the Company in connection with the Build-Out Loan will accrue interest
at three and one-quarter percent (3.25%) per annum and will be payable with interest no later than five (5) years from the date of the
Build-Out Loan. INVO may, in its discretion, secure third party debt in connection with funding the Build-Out Loan.

 

4.3
Physician Employment Agreements. At the Closing, the Provider shall enter into an employment agreement (the “Physician
Employment Agreements”) with Sue Ellen Carpenter, M.D. and, at the election of Provider, David Keenan, M.D. (each, a “Physician”),
in substantially in the form attached as Exhibit C. Each Physician who is an owner of Provider is herein referred to as a “Physician
Owner”.

 

4.4
INVOcell Supply Agreement. At Closing, INVO Bioscience and Company shall enter into a long-term supply agreement, substantially
in the form attached as Exhibit D (the “INVOcell Supply Agreement”), whereby INVO Bioscience will agree to
be the exclusive supplier of the INVOcell and related devices and supplies (the “Products”) to be used at the INVO
Clinic; provided that the INVOcell Supply Agreement will be subject to all applicable terms and conditions set forth in that certain
Distribution Agreement, dated November 12, 2018, by and among Ferring International Center S.A., INVO Bioscience and Bio X Cell, Inc.
The term of the INVOcell Supply Agreement shall be co-terminus with this Agreement.

 

4.5
Intellectual Property Arrangements.

 

(a)
At Closing, the Company and INVO will enter into a long-term intellectual property sublicense agreement (the “INVO IP Sublicense
Agreement”) whereby INVO will sublicense, on a non-exclusive basis, to the Company, the rights to use certain of INVO Bioscience’s
trademarks, copyrights, the INVO Technologies and other INVO intellectual property, including at the INVO Clinic, pursuant to the INVO
IP Sublicense Agreement, a copy of which is attached as Exhibit E. The term of the INVO IP Sublicense Agreement shall be co-terminus
with this Agreement.

 

(b)
At Closing, the Company and the Provider will enter into a long-term intellectual property license agreement (the “Provider
IP License Agreement”) whereby the Provider will license, on a non-exclusive basis to the Company, the rights to use certain
trademarks, copyrights and other Provider intellectual property to be utilized by the Company in connection with its management of the
INVO Clinic, pursuant to the Provider IP License Agreement, a copy of which is attached as Exhibit F. The term of the Provider
IP License Agreement shall be co-terminus with this Agreement.

 

    	-3-

    	 

    

 

(c)
At Closing, the Company, Provider and INVO Bioscience will enter into a long-term intellectual property license agreement (the “JV
IP License Agreement”) whereby the Company and Provider will license, on a non-exclusive basis, to INVO Bioscience, the rights
to use Company’s and/or Provider’s information and technology related to all therapeutic, prophylactic and diagnostic uses
of medical devices or pharmaceutical products involving assisted reproductive technology (including infertility treatment) in humans
and any intellectual property arising therefrom, that Company or Provider creates, generates, derives, develops or conceives, or otherwise
obtains rights in, after the Effective Date, pursuant to the JV IP License Agreement, a copy of which is attached as Exhibit G.
The term of the JV IP License Agreement shall be co-terminus with this Agreement.

 

4.6
Regulatory Authorizations; Consents.

 

(a)
The Parties shall use commercially reasonable best efforts to obtain the authorizations, consents, orders and approvals necessary for
their execution and delivery of, and the performance of their obligations pursuant to, this Agreement. As promptly as practicable after
the date of this Agreement, the Parties shall make, or cause to be made, all filings required by any Laws to be made to consummate the
transactions contemplated under this Agreement.

 

(b)
The Parties each shall keep the other apprised of the status of matters relating to completion of the transactions contemplated hereby.
The Parties shall furnish to each other all information required for any application or other filing under the rules and regulations
of any applicable Law in connection with the transactions contemplated by this Agreement unless (1) such information includes data which
is proprietary or confidential or (2) the furnishing of such information would (A) violate the provisions of any Laws or any confidentiality
agreement that is binding on such Party, or (B) cause the loss of the attorney-client privilege with respect thereto; provided that
each such Party shall use its commercially reasonable efforts to promptly communicate to the other Parties the substance of any such
communication, whether by redacting parts of such material communication or otherwise, so that such communication would not violate any
Laws, any such confidentiality agreement, or cause the loss of the attorney-client privilege.

 

4.7
No Conflicting Agreements. No Party shall enter into any agreements or arrangements of any kind with any Person with respect to
any Units or other equity securities of the Company or the transactions contemplated hereunder that would prohibit such Party from complying
with the applicable provisions of this Agreement (whether or not such agreements or arrangements are with other Parties or with Persons
that are not a party to this Agreement).

  

ARTICLE
5.

REPRESENTATIONS AND WARRANTIES OF THE PARTIES

 

5.1
Representations and Warranties of Provider. Provider represents and warrants to INVO that the following representations and warranties
(in addition to any representations and warranties made by it elsewhere in this Agreement) are accurate and complete as of the date hereof
and as of the Closing:

 

(a)
Organization and Good Standing. Provider is a limited liability company duly organized, validly existing, and in good standing
under the laws of the State of Georgia. Provider is duly qualified and licensed to do its business and is in good standing in each jurisdiction
in which the business transacted by it or the nature or location of its assets makes such qualification or licensing necessary, except
where the failure to be so qualified or licensed or in good standing would not have a Material Adverse Effect.

 

    	-4-

    	 

    

 

(b)
Organizational Powers. Provider has and holds the right and power, and all licenses, permits, authorizations, and approvals (governmental
or otherwise), necessary to entitle Provider to own and operate its properties and assets, and to carry on its business.

 

(c)
Authority. Provider has the full right, power, and authority to execute and deliver this Agreement and the other agreements contemplated
hereby to which it is signatory, and to consummate the transactions contemplated hereby and thereby. All acts and other proceedings required
to be taken by Provider in order to enable Provider to carry out this Agreement and the transactions contemplated hereby have been taken.

 

(d)
Binding Effect. This Agreement has been duly executed and delivered by Provider and (together with any agreements or instruments
to be executed and delivered at the Closing by Provider) constitutes a legal, valid and binding obligation of Provider, enforceable in
accordance with its terms.

 

(e)
Consents. Except for those obtained or made at or prior to the Closing and except where the failure to so obtain would not have
a Material Adverse Effect, neither the execution and delivery of this Agreement nor the consummation of any transaction contemplated
hereby requires Provider to obtain any consent, permit, or approval, or to make any filing or registration, under any Laws or Order applicable
to Provider or under any corporate charter, bylaw, limited liability operating agreement, Contract, lease, license, loan agreement, promissory
note, deed of trust, mortgage, or other instrument, undertaking, commitment, or agreement to which Provider is a party or is otherwise
subject.

 

(f)
Litigation. There is no material litigation, arbitration, investigation, tax audit, or other claim or proceeding pending or, to
the Knowledge of Provider, threatened against Provider arising out of the Provider Business. Provider is not in default under any Order
to which it is bound or otherwise subject related to the Provider Business. To the Knowledge of Provider, there are no audits, investigations,
reviews, or other inquiries (or proposed audits, investigations, reviews, or inquiries) by any Governmental Authority regarding the Provider
Business, or any disputes or potential disputes with any Governmental Authority regarding any aspect of the Provider Business.

 

(g)
Compliance with Laws. Provider is in compliance in all material respects with all applicable Laws pertaining to the Provider Business.
No claim has been made to Provider by any Governmental Authority (and to the Knowledge of Provider, no such claim is anticipated) to
the effect that the Provider Business fails to comply with any Law or that a license, permit, certificate, or authorization (which has
not promptly thereafter been obtained) is required with respect to the operation of its business.

 

(h)
Finders and Brokers. No Person has acted as a finder, broker, or other intermediary on behalf of Provider in connection with this
Agreement or the transactions contemplated hereby, and no Person is entitled to any broker’s or finder’s fee or similar fee
with respect to this Agreement or such transactions as a result of actions taken by Provider.

 

(i)
Actions by Provider. Prior to the Closing, neither Provider nor its Affiliates have caused the Company to take any material actions
or incur any material Liabilities, other than as expressly contemplated by this Agreement or as necessary to effectuate the purposes
of this Agreement and the transactions contemplated by this Agreement.

 

    	-5-

    	 

    

 

5.2
Representations and Warranties of INVO. INVO represents and warrants to Provider that the following representations and warranties
(in addition to any representations and warranties made by it elsewhere in this Agreement) are accurate and complete as of the date hereof
and as of the Closing:

 

(a)
Organization and Good Standing of INVO. INVO is a Delaware limited liability company duly organized, validly existing, and in
good standing under the laws of the State of Delaware. INVO is duly qualified and licensed to do its business and is in good standing
in each jurisdiction in which the business transacted by it or the nature or location of its assets makes such qualification or licensing
necessary, except where the failure to be so qualified or licensed or in good standing would not have a Material Adverse Effect.

 

(b)
Corporate Powers. INVO has and holds the right and power, and all licenses, permits, authorizations, and approvals (governmental
or otherwise), necessary to entitle INVO to own and operate its properties and assets, and to carry on its business.

 

(c)
Authority. INVO has the full right, power, and authority to execute and deliver this Agreement and the other agreements contemplated
hereby to which it is signatory, and to consummate the transactions contemplated hereby and thereby. All acts and other proceedings required
to be taken by INVO in order to enable INVO to carry out this Agreement and the transactions contemplated hereby have been taken.

 

(d)
Binding Effect. This Agreement has been duly executed and delivered by INVO and (together with any agreements or instruments to
be executed and delivered at the Closing by INVO) constitutes a legal, valid and binding obligation of INVO, enforceable in accordance
with its terms.

 

(e)
Consents. Except for those obtained or made at or prior to the Closing and except where the failure to so obtain would not have
a Material Adverse Effect, neither the execution and delivery of this Agreement nor the consummation of any transaction contemplated
hereby requires INVO to obtain any consent, permit, or approval, or to make any filing or registration, under any Laws or Order applicable
to INVO or under any corporate charter, bylaw, limited liability operating agreement, Contract, lease, license, loan agreement, promissory
note, deed of trust, mortgage, or other instrument, undertaking, commitment, or agreement to which INVO is a party or is otherwise subject.

 

(f)
Litigation. There is no material litigation, arbitration, investigation, tax audit, or other claim or proceeding pending or threatened
against INVO arising out of the INVO Business. INVO is not in default under any Order to which it is bound or otherwise subject related
to the INVO Business. There are no audits, investigations, reviews, or other inquiries (or proposed audits, investigations, reviews,
or inquiries) by any Governmental Authority regarding the INVO Business, or any disputes or potential disputes with any Governmental
Authority regarding any aspect of the INVO Business.

 

(g)
Compliance with Laws. INVO is in compliance in all material respects with all applicable Laws pertaining to the INVO Business.
No claim has been made to INVO by any Governmental Authority and no such claim is anticipated to the effect that the INVO Business fails
to comply with any Law or that a license, permit, certificate, or authorization (which has not promptly thereafter been obtained) is
required with respect to the operation of such INVO Business.

 

(h)
Finders and Brokers. No Person has acted as a finder, broker, or other intermediary on behalf of INVO in connection with this
Agreement or the transactions contemplated hereby, and no Person is entitled to any broker’s or finder’s fee or similar fee
with respect to this Agreement or such transactions as a result of actions taken by INVO.

 

    	-6-

    	 

    

 

(i)
Actions by INVO. Prior to the Closing, neither INVO nor its Affiliates have caused the Company to take any material actions or
incur any material Liabilities, other than as expressly contemplated by this Agreement or as necessary to effectuate the purposes of
this Agreement and the transactions contemplated by this Agreement.

 

5.3
Securities Representations. Each Party severally, and not jointly, represents that:

 

(a)
The Units that are allocable to such Party are being acquired for the Party’s own account and not with a view to the public distribution
of any of the Units. The Party will not sell, hypothecate or otherwise transfer any of the Units except in accordance with applicable
federal and state securities Laws.

 

(b)
Each Party understands that the offering and the sale of Units pursuant to this Agreement are intended to be exempt from registration
under the Securities Act by virtue of Section 4(2) of the Securities Act and Regulation D under the Securities Act.

 

(c)
Each Party understands that: (i) the Units have not been registered or qualified under the Securities Act or the securities Laws of the
State of Delaware or any other state, and neither the Securities and Exchange Commission nor any state or other regulatory authority
has made any recommendation or finding concerning the value of the Units; (ii) there is no assurance that the Party will be able to sell
the Units at a purchase price that Party deems reasonable; (iii) the Units may be offered, sold or otherwise transferred by the Party
only if (a) the transaction is registered and qualified under the applicable provisions of federal and state securities laws or if exemptions
from such registration and qualification are available; and (b) all conditions applicable to such offer, sale or transfer set forth in
LLC Agreement are satisfied; (iv) the satisfaction of these securities registration exemptions is the Party’s responsibility; and
(v) neither the Company nor the other Party is under any obligation to assist the Party in satisfying these exemptions, and the Company
does not intend to register any subsequent transaction by the Party under applicable federal and state securities Laws.

 

(d)
No oral or written representations or recommendations have been made, and no oral or written information has been furnished, to the Party
regarding the advisability of acquiring the Units. The Party (including its professional advisors, if any) has had sufficient opportunity
to ask questions and receive answers concerning the terms and conditions of the issuance of the Units.

 

(e)
Each Party has such knowledge and experience in financial and business matters that the Party is capable of evaluating the merits and
risks of an investment in the Company and of making an informed investment decision. Each Party is an “accredited investor”
as defined in Rule 501 of the Securities Act.

 

ARTICLE
6.

CONDITIONS TO CLOSING

 

6.1
Mutual Conditions to Closing. The obligation of the Parties to consummate the Closing is subject to the fulfillment, at or prior
to the Closing, of the following conditions, any one or more of which may be waived in writing by such Party:

 

(a)
Core Transaction Documents. At or before the Closing, each Party shall have executed and delivered to the other Party the following,
in form and substance reasonably acceptable to the other Party (the “Core Transaction Documents”), and, where applicable,
such Core Transaction Documents shall be deemed effective at the Closing:

 

    	-7-

    	 

    

 

(i)
Execution and delivery of the Certificate of Formation of the Company, duly issued by the Delaware Secretary of State;

 

(ii)
Execution and delivery of the LLC Agreement, executed by each Party;

 

(iii)
Execution and delivery of the Management Services Agreement, and all attachments thereto, executed by Company and Provider;

 

(iv)
Execution and delivery by the Company of the Build-Out Loan;

 

(v)
Execution and delivery by the Company of the INVOcell Supply Agreement;

 

(vi)
Execution and delivery by the Company of the INVO IP Sublicense Agreement;

 

(vii)
Execution and delivery by the Company of the Provider IP License Agreement; and

 

(viii)
Execution and delivery by the Company and Provider of the JV IP License Agreement.

 

(b)
No Violation of Law. No Law or Order that prohibits, enjoins or otherwise materially restrains the consummation of the transactions
contemplated by this Agreement shall have been enacted, entered, issued, promulgated or enforced; provided, however, that
in such instance, the Parties agree to cooperate with each other in good faith and use commercially reasonable efforts to cause any such
Law or Order to be vacated or lifted.

 

(c)
Licenses and Governmental Approvals. All licenses, permits, governmental and regulatory approvals and certifications required
to be obtained for the consummation of the transactions contemplated hereby and the operation of the Company Business.

 

(d)
Determination of Initial Provider Loan Terms. The Parties will work in good faith to determine the amount and terms for a loan,
to be made after Closing, in one or more tranches to the Provider to support the start-up operations of the Provider, including amounts
for Physician Employee salaries and any related benefits (the “Provider Loan” and together with the Build-Out Loan,
the “Loans”). The Company shall use a portion of the INVO Contribution to fund the Provider Loan. Following the Closing
Date, the Parties acknowledge and agree that any increase in the amount of or changes to the timing for the Provider Loan shall be determined
by the Board of Managers pursuant to the LLC Agreement; provided that unless changed by the Board of Managers, the amount payable to
the Company by the Provider in connection with the Provider Loan will accrue interest at the applicable federal rate for the month in
which a portion of the Provider Loan is made by the Company, and will be payable, with interest, no later than five (5) years from the
date the Provider Loan is issued by Company.

 

6.2
Condition to the Obligations of Provider. The obligation of Provider to consummate the Closing is subject to the fulfillment,
at or prior to the Closing, of the following conditions, any one or more of which may be waived in writing by Provider:

 

(a)
Representations and Warranties; Covenants of INVO. INVO’s representations and warranties in ARTICLE 5 shall be true
and correct in all respects on the date hereof and as of the date of the Closing. On or before the Closing Date, INVO shall have performed
and complied with all covenants and agreements required to be performed or complied with by INVO prior to the Closing under this Agreement.

 

    	-8-

    	 

    

 

(b)
Closing Deliveries of INVO. At or before the Closing, INVO shall have executed and delivered to Provider the following, in form
and substance reasonably acceptable to Provider (the “INVO Closing Documents”), and, where applicable, such INVO Closing
Documents shall be deemed effective at the Closing:

 

(i)
The INVO IP Sublicense Agreement, executed by INVO;

 

(ii)
The INVOcell Supply Agreement, executed by INVO Bioscience;

 

(iii)
All documents required for effectuation of the Build-Out Loan, executed by INVO;

 

(iv)
A certificate of the Secretary or an Assistant Secretary (or equivalent officer) of INVO certifying that attached thereto are true and
complete copies of all resolutions adopted by the governing board and member of INVO, authorizing the execution, delivery and performance
of this Agreement and the other transaction documents and the consummation of the transactions contemplated hereby and thereby, and that
all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated
hereby and thereby;

 

(v)
A good standing certificate from the Delaware Secretary of State, dated within ten (10) days of the date of the Closing.

 

(vi)
All other customary instruments of transfer or assumption, and other filings or documents, in form reasonably satisfactory to Provider,
as may be required to effect the INVO Contribution;

 

(vii)
Execution and delivery by INVO Bioscience of the JV IP License Agreement; and

 

(viii)
Such other agreements, documents and instruments as may be reasonably requested by Provider.

 

(c)
Documents Satisfactory. All proceedings to be taken and all documents to be executed and delivered in connection with the consummation
of the transactions contemplated hereby shall be reasonably satisfactory as to form and substance to Provider including, but not limited
to, all schedules and exhibits to this Agreement.

 

6.3
Conditions to the Obligations of INVO. The obligation of INVO to consummate the Closing is subject to the fulfillment, at or prior
to the Closing, of the following conditions, any one or more of which may be waived in writing by INVO:

 

(a)
Representations and Warranties; Covenants of Provider. Provider’s representations and warranties in ARTICLE 5 shall
be true and correct in all respects on the date hereof and as of the date of the Closing. On or before the Closing Date, Provider shall
have performed and complied with all covenants and agreements required to be performed or complied with by Provider prior to the Closing
under this Agreement.

 

    	-9-

    	 

    

 

(b)
Closing Deliveries of Provider. At or before the Closing, Provider shall have delivered to INVO the following, in form and substance
reasonably acceptable to INVO (the “Provider Closing Documents”), and, where applicable, such Provider Closing Documents
shall be deemed effective at the Closing:

 

(i)
The Provider IP License Agreement, executed by Provider;

 

(ii)
The Physician Employment Agreements, duly executed by Provider and each Physician, as applicable;

 

(iii)
A certificate of the Secretary of Provider certifying that attached thereto are true and complete copies of all resolutions adopted by
the governing board and members of Provider, authorizing the execution, delivery and performance of this Agreement and the other transaction
documents and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and
effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby;

 

(iv)
A good standing certificate from the Georgia Secretary of State dated within ten (10) days of the date of the Closing; and

 

(v)
all other customary instruments of transfer or assumption, and other filings or documents, in form reasonably satisfactory to INVO, as
may be required to effect the Provider Requirements.

 

(c)
Documents Satisfactory. All proceedings to be taken and all documents to be executed and delivered in connection with the consummation
of the transactions contemplated hereby shall be reasonably satisfactory as to form and substance to Provider and its counsel, including,
but not limited to, all schedules and exhibits to this Agreement.

 

ARTICLE
7.

CONFIDENTIALITY AND NON-COMPETITION

 

7.1
Confidential Information. The Parties’ existing Non-Disclosure Agreement, dated January 26, 2021 (the “NDA”)
will remain in full force and effect, subject to the following amendments: (a) included in the “information related to the transaction”
that is to be kept confidential under the NDA shall be this Agreement, the other agreements contemplated hereby and the substance of
the Parties’ negotiations concerning the same; and (b) the arbitration provisions of this Agreement shall supersede and control
those of the NDA.

 

7.2
Non-Competition.

 

(a)
Except as set forth on Schedule 1, and as set forth in the LLC Agreement, each of the Parties acknowledges and agrees (and will
cause each of its appointed Managers to agree) that for so long as such Person holds any interest (directly or indirectly) in the Company
(the “Restricted Period”), such Person shall not, and shall cause its direct and indirect equity holders (excluding
any of INVO Bioscience’s public shareholders), partners, managers, employees, consultants, agents and Affiliates to not, without
the express written consent of the Company, directly engage in any activity which is competitive, in whole or in part, with the Company
Business, or participate or invest in, or provide or facilitate the provision of financing to, or assist (whether as owner, part-owner,
shareholder, member, partner, director, officer, trustee, executive, agent or consultant, or in any other capacity), any Person in Atlanta,
Georgia (the “Restricted Area”) other than the Company, including any such Person involving, or which is, a family
member of such Member or Manager, whose business, activities, products or services are competitive with some or all of the Company Business,
during the Restricted Period and in the Restricted Area (any such Person or business, a “Competitor”). Notwithstanding
the foregoing, no Member or Manager of the Company shall be prohibited by this Section 7.2 from making a passive investment in
any enterprise the shares of which are publicly traded if such investment constitutes less than one percent (1%) of the equity of such
enterprise.

 

    	-10-

    	 

    

 

(b)
Each of the Parties acknowledges and agrees (and will cause each of its appointed Managers to agree) that during the applicable Restricted
Period, such Person shall not, and shall cause its direct and indirect equity holders, partners, managers, employees, consultants, agents
and Affiliates to not, without the express written consent of the Company, directly or indirectly, solicit, contact, or attempt to solicit
or contact, the Company’s current or prospective customers and suppliers with whom such Member or Manager interacted, or from or
about whom such Member or Manager received confidential information (the “Customers and Suppliers”), for the purpose
of offering or accepting goods or services in the Restricted Area that are competitive with those offered by the Company, on behalf of
any Person other than the Company or any of its Subsidiaries, or otherwise adversely and intentionally interfere with the relationship
between the Company or any of its Subsidiaries and any of their Customers and Suppliers.

 

(c)
Each of the Parties acknowledges and agrees (and will cause each of its appointed Managers to agree) that the purpose of the restrictions
contained in this Section 7.2 is to protect the Company’s legitimate business interests, relationships between the Company
and its or their respective clients and customers, confidential information, workforce stability, and business goodwill; in view of the
nature of the Company’s business, these restrictions are reasonable and necessary to protect these Company interests and in light
of the confidential information provided or to be provided to such Member and the Managers and the additional consideration provided
under this Agreement; and any violation of this Agreement would result in irreparable injury to the Company. In the event of a breach
by any Member or any Manager of any provision of this Section 7.2, the Company shall, in addition to any other legal remedies
available, be entitled to a temporary restraining order and injunctive relief restraining such applicable Member or Manager from the
commission of any breach of this Section 7.2, and, if successful, to recover the Company’s reasonable attorneys’ fees,
costs, and expenses related to the breach. The existence of any claim or cause of action by any Member, any Manager or any of their respective
Affiliates against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement
by the Company of the restrictive covenants contained in this Section 7.2 or to injunctive relief.

 

ARTICLE
8.

INDEMNIFICATION

 

8.1
Survival. Except as described in this ARTICLE 8, (i) all representations and warranties of the Parties contained in this
Agreement or in any document delivered pursuant to this Agreement shall survive the Closing until the expiration of any applicable statute
of limitations relating thereto; and (ii) representations and warranties that are made on a fraudulent basis by a Party shall survive
forever. All covenants of the Parties contained in this Agreement and in the documents delivered pursuant to this Agreement shall survive
the Closing in accordance with their respective terms. A written claim for indemnification may be brought at any time after the Closing
and prior to the end of the applicable survival period (the “Claims Period”). No Party shall be entitled to assert
any indemnification pursuant to this ARTICLE 8 after the expiration of the Claims Period; provided that, if on or prior
to such expiration of the applicable Claims Period a notice of claim shall have been given to the respective Indemnifying Party for such
indemnification, the Indemnified Person shall continue to have the right to be indemnified with respect to the matter or matters to which
such claim relates until such claim for indemnification has been satisfied or otherwise resolved.

 

    	-11-

    	 

    

 

8.2
Agreement to Indemnify. Subject to the terms of this Agreement, each Party (the “Indemnifying Party”) shall
indemnify, defend and hold harmless the other Party and each of its respective officers, directors, managers, agents, representatives,
stockholders, members and employees, and each Person, if any, who controls or may control the Party within the meaning of the Securities
Act (each an “Indemnified Person” and collectively, “Indemnified Persons”) from and against any
and all actual losses, costs, damages, Liabilities and expenses (including reasonable attorneys’ fees, other professionals’
fees, costs of investigation and court costs) (collectively, “Damages”), incurred directly by the Indemnified Person
or indirectly through the Indemnified Person’s interests in the Company, that arise from or result from (i) any failure of any
representation or warranty made by the Indemnifying Party in this Agreement to be true and correct as of the Closing; (ii) any breach
of, or failure to perform, any agreement of the Indemnifying Party that is contained in this Agreement; or (iii) any fact, circumstance,
event, omission or failure to act occurring on or prior to the Closing that relates solely to the conduct of the Indemnifying Party on
or prior to the Closing, including, without limitation, (i) Damages that arise as a result of negligence or willful misconduct by the
Indemnifying Party in connection with the operation of the Provider Business or INVO Business, as applicable, on or prior to the Closing
and (ii) Damages that arise as a result of breaches of any Contract or other agreement by the Indemnifying Party that occur on or prior
to the Closing.

 

8.3
Claim Limits. Notwithstanding anything contained herein to the contrary, Damages shall not include any punitive damages that are
not paid or payable to a third party by an Indemnified Person and shall not include consequential Damages (including, without limitation,
lost profits). The amount of any recovery by an Indemnified Person shall be net of any insurance proceeds recoverable by the Indemnified
Person (but not to the extent that such proceeds are repaid by the Indemnified Person through increased insurance premiums) and net of
any Tax benefits actually received by the Indemnified Person as part of determining Damages.

 

8.4
Mitigation; Exclusive Remedy. Any Indemnified Person shall use its commercially reasonable efforts to mitigate any Damages subject
to indemnification obligations under this Agreement and to timely pursue reasonable remedies against applicable insurers in respect of
any indemnifiable Damages. The indemnification provisions of this ARTICLE 8 shall be the sole and exclusive remedy of the Parties
for monetary damages after the Closing arising out of a breach of this Agreement by the other Party. Nothing herein restricts or prevents
the right of any Party to pursue causes of action for which equitable relief is sought.

 

ARTICLE
9.

TERMINATION

 

9.1
Termination. Notwithstanding anything contained in this Agreement to the contrary, this Agreement may be terminated at any time
prior to the Closing Date:

 

(a)
by Provider by giving written notice to INVO on or after the date that is sixty (60) days after the date hereof, if any of the conditions
set forth in Section 6.3 is not satisfied or waived by such date or has become incapable of fulfillment, unless such satisfaction
has been frustrated or made impossible by any act or failure to act by Provider;

 

(b)
by INVO, by giving written notice to Provider on or on or after the date that is sixty (60) days after the date hereof, if any of the
conditions set forth in Section 6.3 is not satisfied or waived by such date or has become incapable of fulfillment, unless such
satisfaction has been frustrated or made impossible by any act or failure to act by INVO;

 

    	-12-

    	 

    

 

(c)
by Provider, by giving written notice to INVO at any time, if INVO has materially breached any representation, warranty, covenant or
agreement contained in this Agreement and such breach has not been cured within thirty (30) days after Provider’s notice to INVO
of such breach or, if cure is not possible within thirty (30) days, if cure has not been commenced and is not being diligently pursued
within thirty (30) days after such notice;

 

(d)
by INVO, by giving notice to Provider at any time, if Provider has materially breached any representation, warranty, covenant or agreement
contained in this Agreement and such breach has not been cured within thirty (30) calendar days after INVO’s notice to Provider
of such breach or, if cure is not possible within thirty (30) calendar days, if cure has not been commenced and is not being diligently
pursued within thirty (30) calendar days after such notice;

 

(e)
by either Party if any injunction or other judgment, order or decree issued by any court of competent jurisdiction or other statute,
law, rule, legal restraint or prohibition having the effect of permanently restraining, enjoining or otherwise prohibiting the transactions
contemplated under this Agreement shall be issued, in effect and shall have become final and nonappealable; or

 

(f)
by mutual written agreement of Provider and INVO.

 

9.2
Effect. In the event of termination of this Agreement pursuant to Section 9.1, no Party shall have any liability or further
obligation to any other Party, and no Party shall be entitled to any monetary damages or injunctive relief (including specific performance)
as a result of such termination, or any indemnification under ARTICLE 8; provided, however, that in no event shall
any termination of this Agreement limit or restrict the rights and remedies of any Party against any other Party which has intentionally
and willfully breached any of the agreements or other provisions of this Agreement prior to the termination hereof; and provided further,
that Company’s and Provider’s respective repayment obligations with respect to the Loans shall remain in full force and effect;
and provided, finally, that the provisions of ARTICLE 10 shall remain in full force and effect.

 

ARTICLE
10.

MISCELLANEOUS

 

10.1
Definitions. Capitalized terms used in this Agreement will have the meanings assigned to such terms as set forth on Schedule
2 hereto.

 

10.2
Information Disclosure. No information or knowledge obtained by a Party pursuant to this Agreement shall be deemed to qualify,
modify, or limit any representation or warranty of the other Party contained in this Agreement or elsewhere.

 

10.3
Legal Privileges. The Parties acknowledge and agree that all attorney-client, work product and other legal privileges that may
exist with respect to a Party’s involvement in the Company Business shall, from and after the Closing Date, be deemed joint privileges
of the Parties. Each Party shall use, and cause the Company to use, all commercially reasonable efforts after the Closing Date to preserve
all privileges, and no Party shall knowingly waive, or cause the Company to knowingly waive, any such privilege without the prior written
consent of the other Party (which consent shall not be unreasonably withheld or delayed).

 

    	-13-

    	 

    

 

10.4
Dispute Resolution

 

(a)
Each dispute between the Parties as to the appropriate construction, enforcement and interpretation of the provisions of the Agreement
will be resolved pursuant to this Section 10.4.

 

(b)
Prior to invoking the arbitration process, a Party seeking to invoke the dispute resolution process hereunder will provide prior written
notice of such dispute to the other Party. Within seven (7) days after receipt of notice from the Party invoking the dispute resolution
process, the Parties shall, through their duly appointed representatives, meet informally to discuss the areas of disagreement and to
negotiate in good faith regarding possible solutions (the “Informal Meeting”).

 

(c)
If the Parties do not resolve the dispute at the Informal Meeting, then, within seven (7) days after such meeting, the parties will name
a neutral mediator to conduct mediation proceedings; provided, however, that if the Parties are unable to agree on a single
mediator within fourteen (14) days following the Informal Meeting, then the Parties agree that a mediator will be selected in accordance
with the alternative dispute resolution process established by the American Health Lawyers Association (“AHLA”). The
mediator will have no authority to impose a resolution, but will work with the Parties to reach a mutually acceptable solution. All parties
involved in the dispute will give the mediator their full cooperation and will participate in good faith in all sessions convened by
the mediator. The costs of engaging such mediator shall be borne by the Company.

 

(d)
If the Parties do not resolve the dispute via the AHLA mediation process, then within thirty (30) days of the conclusion of same, either
Party may submit the dispute to binding arbitration, which arbitration will be conducted consistent with the applicable procedures outlined
in the LLC Agreement.

 

10.5
Governing Law. This Agreement and any action instituted by any party with respect to matters arising hereunder shall be governed
by and construed in accordance with the laws of the State of Delaware applicable to Contracts made and performed in such State and without
regard to conflicts of law doctrines.

 

10.6
Consistency with Governing Documents of the Company. In the event of an inconsistency or ambiguity between any provision in this
Agreement and a provision in the Certificate of Formation or LLC Agreement of the Company, the Parties agree to amend such documents
as necessary to make provisions thereof consistent with this Agreement.

 

10.7
Counterparts; Headings; Execution. This Agreement may be executed in one or more counterparts, each of which shall be deemed an
original but both of which together shall constitute one and the same instrument. Any counterpart or other signature delivered by PDF
or facsimile shall be deemed for all purposes as a valid execution and delivery of this Agreement by that Party. The descriptive headings
of the Articles, Sections and subsections of this Agreement are for convenience only and do not constitute a part of this Agreement.

 

10.8
No Third-Party Beneficiaries. Except for Indemnified Persons as set forth in ARTICLE 8, this Agreement shall be binding
upon and inure solely to the benefit of the Parties and the Company and their permitted assigns and nothing herein, express or implied,
is intended to or shall confer upon any Person, other than the Parties and the Company, any legal or equitable right, benefit or remedy
of any nature whatsoever under or by reason of this Agreement; provided, however, that Provider shall be a third party
beneficiary with respect to the obligations of INVO under this Agreement and INVO shall be a third party beneficiary with respect to
the obligations of Provider under this Agreement.

 

    	-14-

    	 

    

 

10.9
Notices. Any notice or other communication hereunder must be given in writing and (a) delivered in person; (b) transmitted by
facsimile or electronic mail, provided that any notice so given is also mailed as provided in clause (c); or (c) mailed by certified
or registered mail, postage prepaid, receipt requested, or by reputable overnight delivery service, in each case to the address set forth
below each Party’s name on the signature pages hereto, or to such other address or to such other Person as a Party shall have last
designated by such notice to the other Party. Each such notice or other communication shall be effective if (i) given by facsimile or
electronic mail, when transmitted to the applicable number so specified in (or pursuant to) this Section 10.9 and an appropriate
answerback is received, or if transmitted after 4:00 p.m. local time on the day following the date on which such notice is sent; (ii)
by overnight delivery, one business day following the day on which such notice is sent; (iii) given by mail, three days after such communication
is deposited in the mail with first class postage prepaid, addressed as aforesaid; or (iv) given by any other means, on the day when
actually received at such address.

 

10.10
Waiver; Amendment. Any provision of this Agreement may be amended only by a written instrument signed by both Parties. The waiver
of any right under this Agreement requires only the written consent of the Party waiving such right. A Party’s failure to insist
upon strict compliance with any of the terms or conditions of this Agreement will not be deemed a waiver of such term or condition, nor
will any waiver or relinquishment of, or failure to insist upon strict compliance with, any right hereunder at any one or more times
be deemed a waiver or relinquishment of such right at any other time or times.

 

10.11
Assignment. This Agreement shall be binding upon and inure to the benefit of the Parties named herein and their respective successors
and assigns. No Party may assign this Agreement or any of their rights or obligations hereunder without the prior written consent of
the other Party; which consent may be withheld in such Party’s sole and absolute discretion; provided, that no voluntary
or involuntary assignment or transfer by a Party to this Agreement of any of such Party’s rights or obligations under this Agreement
shall in any manner release such Party of any of its obligations under this Agreement; and provided, further, that notwithstanding
the foregoing, INVO may, at its option, assign any of its rights and obligations hereunder to an Affiliate or Subsidiary upon written
notice to Provider. Furthermore, (a) if a Party is merged or consolidated with or into another entity, the surviving entity shall be
bound by all of the merging or consolidating party’s obligations under this Agreement; and (b) if a Party sells all or substantially
all of its assets to another Person, the purchaser shall be bound by all of the selling Party’s obligations under this Agreement.
The preceding provisions of this Section 10.11 are not intended to amend, terminate or otherwise affect any provisions in the
LLC Agreement.

 

10.12
Entire Agreement. This Agreement, and the documents referenced herein, constitute the entire agreement between the Parties relative
to the subject matter hereof. This Agreement replaces and supersedes all prior written or oral agreements, statements, correspondence,
negotiations and understandings between the Parties with respect to the matters covered by this Agreement.

 

10.13
Severability. If any provision of this Agreement is determined to be invalid, illegal or unenforceable, the remaining provisions
of this Agreement, to the extent permitted by Law, shall remain in full force and effect provided that the essential terms and conditions
of this Agreement for all Parties remain valid, binding and enforceable.

 

10.14
Further Assurances. Each Party agrees to cooperate fully with the other Party and the Company, to take such actions, to execute
such further instruments, documents and agreements, and to give such further written assurances, as may be reasonably requested by the
other Party to evidence and reflect the transactions described herein and contemplated hereby, and to carry into effect the intents and
purposes of this Agreement.

 

    	-15-

    	 

    

 

10.15
Rights Cumulative. Subject to the indemnification limits set forth in ARTICLE 8, (a) each and all of the various rights,
powers and remedies of a Party described in this Agreement will be considered to be cumulative in the event of the breach of any of the
terms of this Agreement; and (b) the exercise or partial exercise of any right, power or remedy will neither constitute the exclusive
election thereof nor the waiver of any other right, power or remedy available to such Party under this Agreement. Furthermore, the obligations
of the Parties under this Agreement are unique. The Parties acknowledge that it may be extremely impracticable to measure damages resulting
from certain defaults under this Agreement. Accordingly, a Party not in default under this Agreement may sue in equity for specific performance
or injunctive relief in the event of a breach of the terms hereof by the other Party.

 

10.16
Liability Limits. Notwithstanding anything to the contrary expressed or implied herein, except for any agreements that he, she
or it may execute in his, her or its individual capacity (and not on behalf of a Party), such as the Physician Employment Agreements,
the owners, members, employees, directors, managers, officers of a Party shall not have personal liability with respect to this Agreement
or the transactions contemplated hereby, except in the case of fraud or willful misconduct.

 

[Remainder
of Page Intentionally Left Blank]

 

    	-16-

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Joint Venture Agreement as of the date first above written.

 

	INVO
    Centers, LLC	 	Bloom
    Fertility LLC
	 	 	 
	By:	INVO
Bioscience, Inc.
	 	By:	/s/
    Sue Ellen Carpenter
	Its:	Managing
    Member	 	Name:	Sue
    Ellen Carpenter, MD
			 	Title:	Managing
    Member
	By:	/s/
    Steven Shum	 	 	 
	Name:	Steven
    Shum	 	 	 
	Its:	Chief
    Executive Officer	 	 	 
	 	                   	 	 	                                    
	Address
    for Notice:	 	Address
    for Notice:
	 	 	 
	INVO
    Centers, LLC

    5582 Broadcast Court

    Sarasota, Florida 342240

    Email: legal@invobio.com	 	Bloom
    Fertility, LLC 

    987 Canton Street, Bldg. 14

    Roswell, GA, 30075

    Attention: Sue Ellen Carpenter, M.D. 

    Email: sekcarpenter@mindspring.com

 

With
a copy (which shall not constitute notice) to:

Sheppard,
Mullin, Richter and Hampton LLP

30 Rockefeller Plaza

New York, NY 10112-0015

Attention: Amanda L. Zablocki, Esq.

 

    	-1-

     

    

 

Schedule
1

 

NON-COMPETITION
EXCEPTIONS

 

None.

 

    	 

     

    

 

Schedule
2

 

DEFINITIONS

 

“Affiliates”
means with respect to any Person, any other Person directly or indirectly controlling, controlled by or under common control with the
first Person. For the purposes of this definition, “control,” when used with respect to any Person, means the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through
the ownership of voting securities, by Contract or otherwise, and the terms “controlling” and “controlled” have
meanings correlative to the foregoing. With respect to any natural Person, “Affiliate” will include such Person’s
grandparents, any descendants of such Person’s grandparents, such Person’s spouse, the grandparents of such Person’s
spouse and any descendants of the grandparents of such Person’s spouse (in each case, whether by blood, adoption or marriage).

 

“Agreement”
has the meaning set forth in the Preamble.

 

“Board”
has the meaning set forth in the LLC Agreement.

 

“Capital
Contribution” has the meaning set forth in the LLC Agreement.

 

“Claims
Period” has the meaning set forth in Section 8.1.

 

“Closing”
has the meaning set forth in ARTICLE 3.

 

“Closing
Date” has the meaning set forth in ARTICLE 3.

 

“Company”
has the meaning set forth in the Recitals.

 

“Company
Business” means (i) the business of managing a medical practice offering assisted reproductive technology, fertility/infertility
treatments, and/or other similar women’s healthcare services and (ii) owning and/or operating an embryology laboratory or providing
any similar clinical laboratory services.

 

“Company
Change of Control” means (a) any merger, consolidation or other form of corporate reorganization of the Company with a non-Affiliate
of the Company in which the direct existing equity holders of the Company immediately prior to such transaction collectively own less
than fifty percent (50%) of the Company’s (or the surviving entity, if not the Company) voting power or economic value immediately
after such transaction, (b) a sale of securities of the Company to a non-Affiliate of the Company representing at least fifty percent
(50%) of the voting power or economic value of the Company, or (c) sale or license of all or substantially all of the Company’s
assets to one or more non-Affiliates of the Company. For the avoidance of doubt, a Company Change of Control does not include any transaction
involving the sale or transfer of securities or assets of any shareholder or parent entity of the Company including, but not limited
to, Provider or INVO.

 

“Competitor”
has the meaning set forth in Section 7.2(a).

 

“Contracts”
means any written contract, agreement, license, lease, guaranty, indenture, sales or purchase order or other legally binding commitment
in the nature of a contract.

 

“Damages”
has the meaning set forth in Section 8.2.

 

    	 

     

    

 

“Governmental
Authority” means any court, tribunal, arbitrator, authority, agency, commission, official or other instrumentality of the United
States, any other country or any state, county, city or other political subdivision of the United States or any other country.

 

“Healthcare
Information Laws” means the (a) Health Insurance Portability and Accountability Act of 1996 (Pub. L. No. 104-191) and any regulations
promulgated thereunder; (b) the Health Information Technology for Economic and Clinical Health Act (Title XIII of the American Recovery
and Reinvestment Act of 2009) and any regulations promulgated thereunder; and (c) any state and local laws regulating the privacy and/or
security of individually identifiable information, including state Laws providing for notification of breach of privacy or security of
individually identifiable information, in each case with respect to the Laws described in clauses (a), (b) and (c) of this definition,
as the same may be amended, modified or supplemented from time to time, any successor statutes thereto, any and all rules or regulations
promulgated from time to time thereunder.

 

“Healthcare
Laws” means all federal and state Laws, rules or regulations relating to the regulation, provision or administration of, or
payment for, healthcare products or services, including, but not limited to (a) the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)),
Sections 1320a-7 and 1320a-7a of Title 42 of the United States Code, the Physician Self-Referral Law, commonly known as the “Stark
Law” (42 U.S.C. §§ 1395nn and 1396b), the civil False Claims Act (31 U.S.C. §3729 et seq.), the Federal Criminal
False Claims Act (18 U.S.C. § 287), the False Statements Relating to Health Care Matters Law (18 U.S.C. § 1035), Health Care
Fraud (18 U.S.C. § 1347), or any regulations promulgated pursuant to such statutes, or similar state or local statutes or regulations;
(b) Medicare (Title XVIII of the Social Security Act) and the regulations promulgated thereunder; (c) Medicaid (Title XIX of the Social
Security Act) and the regulations promulgated thereunder as well as comparable state Medicaid statutes and regulations; (d) TRICARE (10
U.S.C. § 1071 et seq.) and the regulations promulgated thereunder; (e) the Emergency Medical Treatment and Labor Act (42 U.S.C.
§ 1395dd) and the regulations promulgated thereunder; (f) the Clinical Laboratory Improvement Act (42 U.S.C. § 263a, et seq.);
(g) any accreditation standards of applicable healthcare accreditation bodies; (h) Laws regarding the professional standards of health
care professionals; (i) Laws regulating the ownership or operation of a health care facility or business, or assets used in connection
therewith, the provision of management or administrative services in connection with the operation of a health care facility or business,
the employment of professionals by non-professionals, fee splitting and certificates of operations and authority; (j) any Laws insofar
as they purport to regulate medical waste or impose requirements relating to medical waste; (k) quality and safety Laws relating to the
regulation, storage, provision or administration of, or payment for, healthcare products or services and (l) Laws governing patient confidentiality
and privacy, including the Healthcare Information Laws, each of (a) through (l) as amended from time to time.

 

“Indemnifying
Party” has the meaning set forth in Section 8.2.

 

“Indemnified
Persons” has the meaning set forth in Section 8.2.

 

“INVO”
has the meaning set forth in the Preamble.

 

“INVO
Business” means the business as operated by INVO immediately prior to the Closing.

 

“INVO
Closing Documents” has the meaning set forth in Section 6.2(b).

 

“INVO
Contribution” has the meaning set forth in Section 2.1.

 

“INVO
IP Sublicense Agreement” has the meaning set forth in Section 4.6(a).

 

    	 

     

    

 

“Knowledge”
means (a) in the case of an individual, as to a particular fact or matter, that (i) such individual is actually aware of such fact or
matter, or (ii) a prudent individual would reasonably be expected to discover or otherwise become aware of such fact or matter in the
course of conducting a reasonable investigation concerning the existence of such fact or matter; and (b) in the case of a Party, as to
a particular fact or matter, the Knowledge (as defined in clause (a) above) as to such fact or matter of any individual who is serving
as a director, manager, officer, or similar position of such Person or any employee of such Person who is charged with primary responsibility
for the area of the operations related to such fact or matter, which for purpose of this Agreement shall mean Sue Ellen Carpenter, M.D.
with respect to Provider.

 

“Laws”
means any statute, law, ordinance, regulation, rule, code requirements of common law, or other requirement of any Governmental Authority,
including, without limitation, the Healthcare Laws and all binding regulations, standards, policies or guidelines promulgated or issued
pursuant to such acts and any similar applicable and binding laws, regulations, policies or guidelines.

 

“Liabilities”
means debts, liabilities and obligations, whether accrued or fixed, absolute or contingent, matured or unmatured, determined or determinable,
known or unknown, including those arising under any Law, action or governmental order and those arising under any Contract, agreement,
instrument, commitment or undertaking.

 

“LLC
Agreement” has the meaning set forth in the Recitals.

 

“Manager”
has the meaning set forth in the LLC Agreement.

 

“Material
Adverse Effect” means any fact, change, event, result, occurrence, effect or circumstance, individually or together with other
facts, changes, events, results, occurrences, effects or circumstances, the effect of which is, or is reasonably likely to be in the
future, materially adverse to (a) the Company Business, earnings, operations, properties, results of operations or condition (financial
or otherwise) of the Company, taken as a whole; provided, however, that Material Adverse Effect shall not include any change,
event or circumstance to the extent resulting from, relating to or arising out of: (i) general economic conditions, except to the extent
such changes or conditions have a disproportionate adverse impact on either of the Parties or the Provider Business or the INVO Business,
as applicable, as compared to other Persons or participants in the industries in which the Parties conduct the Company Business; (ii)
national or international political or social actions or conditions, including the engagement by any country in hostilities, whether
commenced before or after the date hereof, and whether or not pursuant to the declaration of a national emergency or war, or the occurrence
of any military or terrorist attack; (iii) any actions taken, or failures to take action, in each case, to which the Parties have mutually
consented to in writing; (iv) the compliance of the Parties with the terms of this Agreement and the other agreements contemplated hereby;
or (b) the ability of the Parties to consummate the transactions contemplated by this Agreement.

 

“NDA”
has the meaning set forth in Section 7.1.

 

“Order”
means any award, decision, injunction, judgment, order, ruling, subpoena, or verdict entered, issued, made, or rendered by any Governmental
Authority or by any arbitrator.

 

“Ordinary
Course of Business” means (a) actions taken in the Ordinary Course of Business of a Person consistent with past custom and
practice (including with respect to quantity, quality and frequency) of such Person; (b) actions taken that are similar in nature to
actions customarily taken in the ordinary course of the normal day-to-day operations of other Persons that are in the industry in which
the relevant Person and its Subsidiaries do business; or (c) actions taken that are consistent with such Person’s and/or operating
plan which are approved by the Board.

 

    	 

     

    

 

“Party”
and “Parties” have the meanings set forth in the Preamble.

 

“Person”
shall be construed broadly and shall include an individual, a partnership, a corporation, an association, a joint stock company, a limited
liability company, a trust, a joint venture, an unincorporated organization, a Governmental Authority or any department, agency or political
subdivision thereof, and any other entity or organization.

 

“Physician
Employee” means a physician employed by the Provider pursuant to a Physician Employment Agreement.

 

“Physician
Owner” means each Physician Employee who is a member of Provider.

 

“Physician
Employment Agreement” has the meaning set forth in Section 4.4.

 

“Provider”
has the meaning set forth in the Preamble.

 

“Provider
Business” means the business operated by Provider immediately prior to the Closing.

 

“Provider
Closing Documents” has the meaning set forth in Section 6.3.

 

“Provider
IP License Agreement” has the meaning set forth in Section 4.6(b).

 

“Provider
Requirements” has the meaning set forth in the LLC Agreement.

 

“Restricted
Period” has the meaning set forth in Section 7.2(a).

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Subsidiary”
means, with respect to any Person, any corporation, limited liability company, partnership, association or business entity of which (i)
if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any Provider
contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly,
by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (ii) if a limited liability company,
partnership, association or other business entity (other than a corporation), a majority of partnership or other similar ownership interest
thereof is at the time owned or controlled, directly or indirectly, by any Person or one or more Subsidiaries of that Person or a combination
thereof. For purposes hereof, a Person or Persons shall be deemed to have a majority ownership interest in a limited liability company,
partnership, association or other business entity (other than a corporation) if such Person or Persons shall be allocated a majority
of limited liability company, partnership, association or other business entity gains or losses or shall be or control any managing director
or general partner of such limited liability company, partnership, association or other business entity. For purposes hereof, references
to a “Subsidiary” of any Person shall be given effect only at such times that such Person has one or more Subsidiaries, and,
unless otherwise indicated, the term “Subsidiary” refers to a Subsidiary of the Company.

 

“Taxes”
means all federal, state, local and foreign taxes and installments of estimated taxes, property taxes, assessments, deficiencies, levies,
imports, duties, license fees, registration fees, withholdings, or other similar charges of every kind, character or description imposed
by any Governmental or quasi-Governmental Authorities, and any interest, penalties or additions to tax imposed thereon or in connection
therewith.

 

“Unit”
means a membership interest of the Company, as defined in the LLC Agreement.

 

[Remainder
of Page Intentionally Left Blank]Exhibit
10.2

 

THE
UNITS REPRESENTED BY THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES ACT (COLLECTIVELY,
“SECURITIES LAWS”). THE UNITS MAY NOT BE SOLD, OFFERED FOR SALE OR OTHERWISE TRANSFERRED, AND THE HOLDER OF
UNITS MAY NOT ENGAGE IN HEDGING TRANSACTIONS INVOLVING THE UNITS, EXCEPT IN COMPLIANCE WITH THIS AGREEMENT AND UNLESS THE UNITS (i) ARE
REGISTERED UNDER THE SECURITIES LAWS OR (ii) ARE EXEMPT FROM REGISTRATION UNDER THE SECURITIES LAWS AND, IN THE SOLE DISCRETION OF THE
COMPANY, THE COMPANY IS PROVIDED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. THE TRANSFER
OF THE UNITS REPRESENTED BY THIS AGREEMENT IS FURTHER SUBJECT TO THE CONDITIONS SPECIFIED IN THIS AGREEMENT AMONG THE MEMBERS AND THE
COMPANY.

 

Bloom
INVO LLC

 

LIMITED
LIABILITY COMPANY AGREEMENT

 

This
Limited Liability Company Agreement (this “Agreement”) of Bloom INVO LLC (the “Company”),
a Delaware limited liability company, is made as of June 28, 2021, by and among the Company and the Members listed on the signature page
hereto. Company and Members may be referred to individually as a “Party” and together as the “Parties.”

 

RECITALS

 

WHEREAS,
INVO Centers, LLC (“INVO”), a Delaware limited liability company, is an Affiliate of INVO Bioscience, Inc.,
a Nevada corporation (“INVO Bioscience”), a medical device company focused on creating simplified, lower cost
treatments for patients diagnosed with infertility, using a patented medical device (the “INVOcell”) and a
revolutionary in vivo method of vaginal incubation (the “INVO Procedure”) that offer patients a more
natural and intimate experience. The INVOcell, the INVO Procedure and related treatments using artificial reproductive technologies pioneered
or created by INVO are collectively referred to as the “INVO Technologies”; and

 

WHEREAS,
Bloom Fertility, LLC, a Georgia limited liability company (“Provider”), whose sole member is Dr. Sue Ellen
Carpenter, a Georgia-licensed physician (“Dr. Carpenter”), is a medical practice in the State of Georgia that
employs and/or contracts with physicians who, by education, training and experience, are qualified to provide fertility and reproductive
medical services; and 

 

WHEREAS,
Provider and INVO desire to establish a joint venture, the Company, for purposes of commercializing the INVO Technologies by establishing
a fertility center that will offer the INVO Technologies, along with related procedures (the “INVO Clinic”);

 

AGREEMENT

NOW
THEREFORE, in consideration of the mutual representations, warranties and covenants set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

    	 

    	 

    

 

Article
1

DEFINED TERMS

1.1
Definitions. Capitalized terms used but not otherwise defined herein shall the meanings set forth in Exhibit A attached
hereto.

 

Article
2

FORMATION AND ORGANIZATION

 

2.1
Formation and Name. The Company was formed on March 10, 2021 when the Certificate of Formation was filed with the Delaware Secretary
of State. The name of the Company is Bloom INVO LLC. All Company business shall be conducted in the name of Bloom INVO LLC or such other
names that comply with Applicable Law as the Board of Managers (as defined in Section 7.2 hereof) of the Company (the “Board”)
may select from time to time.

 

2.2
Principal Place of Business. The principal office of the Company shall be such place as determined by the Board.

 

2.3
Term. The term of the Company commenced with the filing of the Certificate of Formation with the Delaware Secretary of State and
shall continue until the Company is dissolved and all of its assets are liquidated in accordance with the provisions of this Agreement.

 

2.4
No State Law Partnership. The Members intend that the Company (a) shall be taxed as a partnership for all applicable federal and,
to the extent applicable, state and local income tax purposes, and (b) shall not be a partnership or joint venture for any other purpose,
and that no Member shall, by virtue of this Agreement, be a partner or joint venturer of any other Member.

 

2.5
Ownership of Company Property. All property acquired by the Company, real or personal, tangible or intangible, shall be owned
by the Company as an entity, and no Member, individually, shall have any ownership interest therein solely due to her, his or its capacity
as a Member.

 

Article
3

PURPOSE AND POWERS OF THE COMPANY

 

3.1
Purpose. The Company is formed for the purpose of engaging in any lawful activity for which a limited liability company may be
organized in Delaware.

 

3.2
Powers of the Company. Subject to the provisions of this Agreement and unless otherwise directed by the Board, the Company shall
have the power and authority to take any and all actions necessary, appropriate, proper, advisable, incidental or convenient to or for
the furtherance of the purposes set forth in Section 3.1.

 

Article
4

UNITS, MEMBER CONTRIBUTIONS, NATURE OF UnITS AND ESTABLISHMENT OF CAPITAL ACCOUNTS

 

4.1
Units. The equity in the Company shall be represented by the “Units.” The Units shall have the rights,
preferences and privileges, including voting rights, if any, set forth in this Agreement. None of the Units will be represented by certificates
until such time (if any) as the Board determines to issue certificates representing the Units. Unless otherwise set forth in this Agreement,
all Units shall have the same rights and privileges.

 

    	-2-

    	 

    

 

4.2
Authorized Units; Issuance. There are hereby established and authorized for issuance such number of Units as the Board may from
time to time determine. Subject to the terms of Section 4.3(b) below, upon the effectiveness of this Agreement, the Company hereby
agrees to issue to Provider, and Provider hereby agrees to receive from the Company the number of Units set forth opposite Provider’s
name on Exhibit B attached hereto in exchange for Provider’s services, as outlined herein (the “Provider
Requirements”) as consideration; and Company hereby agrees to issue to INVO, and INVO hereby agrees to receive from the
Company the number of Units set forth opposite INVO’s name on Exhibit B attached hereto in exchange for INVO’s
initial Capital Contribution (the “INVO Contribution”) as consideration.

 

4.3
Member Contributions; Provider Vesting.

 

(a)
In connection with the execution of this Agreement and in exchange for receipt of their respective Units, the Members shall act as follows:

 

(i)
INVO Contribution. In consideration for 800 Units, INVO commits to contribute up to Eight Hundred Thousand Dollars ($800,000)
within the twenty-four (24) month period following execution of this Agreement to support the start-up operations of the Company. INVO
will fund the INVO Contribution pursuant to the Company’s reasonable business needs, as mutually agreed to by the Parties in the
Business Plan (as defined in Section 7.9 hereof), and, in exchange for such commitment and funding, INVO received 800 Units. The
INVO Contribution shall be provided by INVO to the Company in increments of Fifty Thousand Dollars ($50,000).

 

(ii)
Provider Requirements. In consideration for 1,200 Units, Provider commits to contribute physician services to the INVO Clinic,
through the efforts of its Physicians, having an anticipated value of up to One Million Two Hundred Thousand Dollars ($1,200,000) over
the course of an anticipated twenty-four (24) month vesting period (“Provider Vesting Period”). During the
Provider Vesting Period, Provider is anticipated to provide the physician services through its Physicians on a 2.0 full-time equivalent,
or “FTE” basis (the “Provider Requirements”). “FTE” means a Physician
employed by or under contract with Provider, working a minimum of thirty (30) hours per week. In exchange for its satisfaction of Provider
Requirements, Provider received 1,200 Units, subject to the vesting schedule described in Section 4.3(b).

 

(b)
Vesting; Forfeiture. During the Provider Vesting Period, up to 11.538 of Provider’s 1,200 Units (the “Available
Weekly Unit Vesting Amount”) shall vest each week in which Provider’s Physicians render least 1.0 FTE of services
(or take Permitted Time Off as provided for in the Physician Employment Agreements). The Provider’s vesting of Units in a given
week will be measured by multiplying the (x) Available Weekly Unit Vesting Amount by (y) a fractional basis, where the numerator is the
actual hours worked by Provider’s Physicians (including Dr. Carpenter) during such week, and the denominator is equal to sixty
(60) hours per week (2.0 FTE); provided, however, that as long as Provider’s Physicians (including Dr. Carpenter)
render, in the aggregate, at least 4,100 total Physician services hours by the end of the Provider Vesting Period (the “Minimum
Provider Commitment”), then any unvested Units at such time will be immediately, fully vested in Provider. Notwithstanding
anything to the contrary in this Agreement, in the event that Provider fails to satisfy fully the Minimum Provider Commitment by the
end of the Provider Vesting Period necessary to fully vest in all 1,200 Units, then the number of unvested Units as of the final date
of the Provider Vesting Period shall immediately be forfeited by Provider. Further, if at any time during the Provider Vesting Period
Dr. Carpenter ceases to render at least 1.0 FTE of services (or take Permitted Time Off as provided for in her Physician Employment Agreement),
then notwithstanding anything to the contrary in this Agreement, the number of unvested Units as of such date shall immediately be forfeited
by Provider.

 

    	-3-

    	 

    

 

(c)
Additional Contributions. No Member shall be required to make any Capital Contribution to the Company, other than as provided
in this Section 4.3. The Members may voluntarily make additional Capital Contributions to the Company upon the request of the
Board of Managers. In the event that any Member is unable or unwilling to contribute its share of additional capital requested by the
Board of Managers pursuant to this Section 4.3(c), the Members may mutually agree that the Member(s) willing to contribute the
additional capital be allowed to contribute the entire required additional capital on any such basis as agreed to by the Members, and
in such event, the ratio of ownership between the Members shall stand modified to the extent of the additional Capital Contribution made
by the contributing Member and the ownership of the non-contributing Member shall stand diluted accordingly. No disproportionate Capital
Contributions or corresponding dilution shall occur absent the mutual written consent of the Members.

 

4.4
Nature of Units. The Units shall for all purposes be personal property. Except as may otherwise be set forth herein, no Member
has any interest in specific Company property, and each Member hereby waives any and all rights such Person may have to initiate or maintain
any suit or action for partition of the Company’s assets.

 

4.5
Capital Accounts. An individual Capital Account shall be established and maintained for each Member in accordance with the rules
of Treasury Regulation Section 1.704-1(b)(2)(iv). Each Member’s Capital Account shall be increased by (a) the amount of money contributed
by such Member to the Company, (b) the Gross Asset Value of property contributed by such Member to the Company (net of liabilities secured
by the contributed property that the Company is considered to assume or take subject to under Section 752 of the Code), and (c) allocations
to such Member of Profits (and any items in the nature of income or gain separately allocated to such Member). Each Member’s Capital
Account shall be decreased by (x) the amount of money distributed to such Member by the Company, (y) the Gross Asset Value of property
distributed to such Member by the Company (net of liabilities secured by the distributed property that the Member is considered to assume
or take subject to under Section 752 of the Code), and (z) allocations to such Member of Losses (and any items in the nature of losses
or deductions separately allocated to such Member). The Capital Accounts also shall be maintained and adjusted as permitted by the provisions
of Treasury Regulation Section 1.704-1(b)(2)(iv)(f) and as required by the other provisions of Treasury Regulation Sections 1.704-1(b)(2)(iv)
and 1.704-1(b)(4). On the transfer of all or a portion of a Member’s Units, the Capital Account of the transferor that is attributable
to the transferred Units shall carry over to the transferee Member in accordance with the provisions of Treasury Regulation Section 1.704-1(b)(2)(iv)(l).

 

4.6
Negative Capital Accounts. No Member shall be required to pay to any other Member or the Company any deficit or negative balance
that may exist from time to time in such Member’s Capital Account (including upon and after dissolution of the Company).

 

4.7
No Withdrawal. No Member shall be entitled to resign from the Company or withdraw all or any portion of such Member’s Contributions
or the balance of such Member’s Capital Account, or to receive any distribution from the Company, except as expressly provided
herein.

 

4.8
Loans from Members.

 

(a)
Loan to Company. INVO commits to issuing debt to the Company in an amount up to Six Hundred Thousand Dollars ($600,000) for construction
or improvements related to the INVO Clinic (the “Build-Out Loan”) upon terms and conditions mutually agreeable
to INVO and Company. Any amount payable to INVO by the Company in connection with the Build-Out Loan will accrue interest at three and
one-quarter percent (3.25%) per annum and will be payable with interest no later than five (5) years from the date of the Build-Out Loan.
INVO may, in its discretion, secure third party debt in connection with funding the Build-Out Loan; provided, however, in
no event shall INVO pledge any part of its Units or assets of the Company as collateral for any third party debt. 

 

    	-4-

    	 

    

 

(b)
Loan to Provider. The Company will provide a loan in one or more tranches to the Provider to support the start-up operations of
the Provider, including the salaries of the Physician Employees and any related benefits (the “Provider Loan”
and together with the Build-Out Loan, the “Loans”). The amount and timing of the Provider Loan shall be decided
upon by the Board and reflected in the Business Plan. The Company shall use a portion of the INVO Contribution to fund the Provider Loan.
Any amount payable to the Company by the Provider in connection with the Provider Loan will accrue interest at the applicable federal
rate for the month in which a portion of the Provider Loan is made by the Company, and will be payable, with interest, no later than
five (5) years from the date the Provider Loan is issued by Company.

 

(c)
Loans by Members. Any loans by Members to the Company shall not be considered Capital Contributions. If any Member advances funds
to the Company in excess of the amounts required hereunder to be contributed by such Member to the capital of the Company, the making
of such advances shall not result in any increase in the amount of the Capital Account of such Member unless otherwise agreed by the
Company and such Member. The amount of any such advances that are not agreed to be additional Capital Contributions shall be a debt of
the Company to such Member and shall be payable or collectible in accordance with the terms and conditions upon which such advances are
made.

 

4.9
No Right to Redemption. Except as otherwise provided in this Agreement, the Company shall not be obligated to redeem any Units
absent the written direction of each Member.

 

Article
5

ALLOCATIONS AND DISTRIBUTIONS

 

5.1
Allocations of Profits and Losses. Except as otherwise provided in this Article 5, Profits and Losses for each Fiscal Year
shall be allocated to the Members as set forth below in this Section 5.1:

 

(a)
Subject to Section 5.1(b) and Section 5.3, and after all Contributions and distributions for each Fiscal Year have been
reflected in the Members’ Capital Accounts, Profits or Losses for each Fiscal Year shall be allocated to the Members in amounts
that would result, to the greatest extent possible, in Capital Account balances for each Member being equal to the amount required to
be distributed pursuant to Section 5.4 to such Member in accordance with the priority and manner provided therein on a hypothetical
liquidation of the Company. In determining the amounts distributable to the Members under Section 5.4 upon a hypothetical liquidation,
it shall be presumed that (i) all of the Company’s remaining assets are sold at their respective Gross Asset Values, without further
adjustment and (ii) the proceeds of such hypothetical sale are applied and distributed in accordance with Section 5.4 hereof.

 

(b)
Special Allocations.

 

(i)
Qualified Income Offset. In the event any Member unexpectedly receives any adjustments, allocations or distributions described
in Treasury Regulation Section 1.704-1(b)(2)(ii)(d)(4), (d)(5) or (d)(6), items of Company income and gain shall be specially allocated
to each such Member in an amount and manner sufficient to eliminate, to the extent required by the Treasury Regulations, the Adjusted
Capital Account Deficit of such Member as quickly as possible; provided that an allocation pursuant to this Section 5.1(b)(i)
shall be made if and only to the extent that such Member would have an Adjusted Capital Account Deficit after all other allocations
provided for in this Article 5 have been tentatively made as if this Section 5.1(b)(i) were not a term of this Agreement.
This Section 5.1(b)(i) is intended to constitute a “qualified income offset” provision as described in Treasury Regulation
Section 1.704-1(b)(2)(ii)(d) and shall be interpreted consistently therewith.

 

    	-5-

    	 

    

 

(ii)
Gross Income Allocation. In the event any Member has a deficit Capital Account at the end of any Fiscal Year that is in excess
of the amount such Member is deemed to be obligated to restore pursuant to the penultimate sentences of Treasury Regulation Sections
1.704-2(g)(1) and 1.704-2(i)(5), each such Member shall be specially allocated items of Company income and gain in the amount of such
excess as quickly as possible; provided that an allocation pursuant to this Section 5.1(b)(ii) shall be made if and only
to the extent that such Member would have a deficit Capital Account in excess of such sum after all other allocations provided for in
this Section 5.1(b) have been tentatively made as if this Section 5.1(b)(ii) and Section 5.1(b)(i) hereof were not
in this Agreement.

 

(iii)
Curative Allocations. The allocations set forth in Sections 5.1(a) and 5.1(b)(i) and 5.1(b)(ii) (collectively, the
“Regulatory Allocations”) are intended to comply with requirements of the Treasury Regulations. It is the intent
of the parties hereto that, to the extent possible, all Regulatory Allocations shall be offset either with other Regulatory Allocations
or with special allocations of other items of Company income, gain, loss or deduction pursuant to this Section 5.1(b)(iii). Therefore,
notwithstanding any other provision of this Article 5 (other than the Regulatory Allocations), the Board shall make such offsetting
special allocations of Company income, gain, loss or deduction in whatever manner it determines appropriate so that, after such offsetting
allocations are made, each Member’s Capital Account balance is, to the extent possible, equal to the Capital Account such Member
would have had if the Regulatory Allocations were not terms of this Agreement and all Company items were allocated pursuant to this Section
5.1.

 

(iv)
Allocations of Withholding. To the extent the Company receives (or is deemed to receive) an amount of income that is net of any
withholding tax, (i) such income shall be allocated among the Members as if the Company received the gross amount of such income before
giving effect to the payment of the withholding tax and (ii) any resulting tax credit shall be allocated among the Members in proportion
to such Member’s allocated share of income or withholding amount (including income allocated pursuant to Section 704(c) of the
Code) to which the credit or withholding amount relates.

 

5.2
Tax Allocations.

 

(a)
Generally. Except as otherwise provided in this Section 5.2, taxable income and loss and all items thereof shall be allocated
to the Members to the greatest extent practicable in a manner consistent with the manner set forth in Section 5.1 and Sections
704(b) and (c) of the Code. Allocations pursuant to this Section 5.2 are solely for federal income tax purposes and shall not
affect, or in any way be taken into account in computing, any Member’s Capital Account or share of Profits and Losses, other items
or distributions pursuant to any provision of this Agreement.

 

(b)
Section 704(c) of the Code. In accordance with Section 704(c) of the Code, income, gain, loss and deduction with respect to any
property contributed to the capital of the Company shall, solely for income tax purposes, be allocated among the Members so as to take
account of any variation between the adjusted basis of such property to the Company for federal income tax purposes and its initial Gross
Asset Value.

 

    	-6-

    	 

    

 

(c)
Adjustments under Section 704(c) of the Code. In the event the Gross Asset Value of any Company asset is adjusted pursuant to
paragraph (b) of the definition of “Gross Asset Value,” subsequent allocations of income, gain, loss and deduction with respect
to such asset shall take account of any variation between the adjusted tax basis of such asset and its Gross Asset Value in the same
manner as, but not necessarily under the same convention(s) or method(s) specifically used by the Company for its allocations made or
to be made, under Section 704(c) of the Code and Treasury Regulations thereunder.

 

(d)
Decisions Relating to Section 704(c) of the Code. Any elections or other decisions relating to allocations under this Section
5.2, including the selection of any allocation method permitted under Treasury Regulation Section 1.704-3, shall be made by the Board.
The Board is hereby authorized to amend this Agreement as necessary to implement the method selected under Treasury Regulation Section
1.704-3.

 

(e)
Changes in Members’ Interests. If during any Fiscal Year or other accounting period of the Company there is a change in
any Member’s interest in the Company, the Board shall allocate Profits or Losses to the Members in the Company in a manner that
complies with the provisions of Section 706 of the Code.

 

(f)
Deductible Payments Treated as Distributions. If any amount claimed by the Company to constitute a guaranteed payment as defined
in Section 707(c) of the Code or a payment to a Member not acting in its capacity as a member under Section 707(a) of the Code is treated
for Federal income tax purposes as a distribution made to a Member in its capacity as a member of the Company, then the following provisions
shall apply:

 

(i)
The Capital Account of the Member who is deemed to have received such distribution shall be reduced to reflect the distribution.

 

(ii)
The Member who is deemed to have received such distribution shall be allocated an amount of Company gross income equal to such payment.

 

(g)
For purposes of Section 5.1, Profits and Losses shall be determined after making the allocation required by this Section 5.2.

 

5.3
Allocations of Cash for Funding of Company Operating Expenses and Reserves, and Payment of Build-Out Loan. Prior to the making
of any distributions pursuant to Section 5.4, the cash of the Company shall be (including collections and cash reserves in excess
of amounts determined as necessary by the Board) shall be allocated to, in the following priority:

 

(a)
first, to fund the operating expenses of the Company, including the satisfaction of any repayment obligations due and owing under any
loans to the Company (including the Build-Out Loan, subject to the limitations set forth herein) and/or any expenses relating to the
financing of the Company;

 

(b)
then, to fund the operating and capital reserves of the Company, as determined by the Board; and then, fifty percent (50%) of any remaining
amount to any unpaid amount of the Build-Out Loan (including both interest and principal, when payable under the terms of the Build-Out
Loan).

 

5.4
Operating Distributions. Subject to the provisions of Section 5.7 and Applicable Law, if there is any cash of the Company
remaining following the allocations of available cash outlined in Section 5.3, then the Company may distribute such remaining
available cash to Provider and INVO in the following order of priority:

 

(a)
first, to INVO until the Hurdle Amount has been reduced to $0;

 

    	-7-

    	 

    

 

(b)
second, to Provider until the amounts distributed to Provider under this subsection (b) equal 150% of the amounts distributed to INVO
under Section 5.4(a); and

 

(c)
thereafter to the Members on a Per Unit Pro Rata Basis.

 

5.5
Fees and Expenses. For the avoidance of doubt, if any fees are paid, or expenses are paid or reimbursed, to a Member or its Affiliates,
such amounts shall not be considered distributions for any purpose under Section 5.4 or otherwise hereunder except as required
by Applicable Law.

 

5.6
Dissolution Expenses and Liquidating Distributions. In the event of the dissolution and liquidation of the Company, the assets
of the Company shall be disbursed in the following order of priority:

 

(a)
first, to make payment of all debts and liabilities owing to creditors and the expenses of dissolution or liquidation;

 

(b)
second, to establish such reserves as reasonably deemed by the Board as necessary for any contingent or unforeseen liabilities or obligations
of the Company;

 

(c)
third, to make payment of the Build-Out Loan, until the Build-Out Loan (including both interest and principal, when payable under the
terms of the Build-Out Loan) have been repaid in full;

 

(d)
fourth, to repay any Capital Contributions of INVO not previously repaid to INVO under Section 5.4(a);

 

(e)
fifth, to Provider until the amount distributed to Provider under this subsection (e) equals 150% of the amount distributed to INVO under
Section 5.6(d); and

 

(f)
thereafter, to the Members on a Per Unit Pro Rata Basis.

 

5.7
Tax Distributions. On or before April 15th of each Fiscal Year, the Company shall distribute to each Person who was a Member during
the immediately preceding Fiscal Year of the Company an amount of cash (the “Tax Distribution Limitation Amount”)
equal to forty-seven percent (47%) (such rate to be subject to one or more equitable adjustments by the Board to reflect the highest
combined marginal federal and state income tax rates, taking into account deductibility of state taxes against federal income, then applicable
to an individual residing or a corporation conducting all of its activities in Georgia, whichever is higher, but taking into account
any reduced rates of taxation for particular items of Company income and gain that are generally applicable to Members) of (a) the total
amount of cumulative taxable income and gain allocated to such Member for federal income tax purposes in the Company income tax return
filed or to be filed with respect to such Fiscal Year and prior Fiscal Years, over (b) the total cumulative amount of losses and deductions
allocated to such Member for federal income tax purposes in the Company’s income tax return filed or to be filed with respect to
such Fiscal Year and prior Fiscal Years, reduced by any prior distributions pursuant to this Section 5.7 with respect to such Fiscal
Year and prior Fiscal Years; provided that income attributable to a distribution under Section 5.4 that is treated as a payment under
Sections 707(a) or 707(c) of the Code shall be treated as an allocation of taxable income of the Company to the recipient of such distribution.
Notwithstanding the foregoing, no distribution shall be made or required under this Section 5.7 with respect to any Fiscal Year to any
Member in excess of the Tax Distribution Limitation Amount. In the discretion of the Board, distributions under this Section 5.7 may
be made on an estimated basis each quarter; if such estimated distributions exceed the actual amount required on April 15th, such Member
receiving excess distributions shall be given a credit balance, and such excess shall be deducted from such Member’s next distribution(s)
under this Section 5.7 (until fully repaid). No distribution under this Section 5.7 shall be made if the making of such distribution
would constitute a violation of the Act or any other Applicable Law or order of any court of competent jurisdiction or any contract or
agreement by which the Company is bound. Furthermore, no distributions shall be made under this Section 5.7 after the dissolution of
the Company or in connection with its winding up and liquidation. Distributions made under this Section 5.7 shall be credited to each
Member as if such Member had received such distribution in accordance with Section 4, and so shall be treated as advances against, and
reduce by a corresponding amount, future distributions to such Member under such section. For the avoidance of doubt, and notwithstanding
any provisions in this Agreement to the contrary, the Members acknowledge and agree that Provider shall be entitled to receive distributions
under this Section 5.7 without regard to the Hurdle Amount.

 

    	-8-

    	 

    

 

5.8
Withholding. Notwithstanding any other provision of this Agreement, each Member hereby authorizes the Company to withhold and
to pay over, or otherwise pay, any withholding or other taxes payable by the Company (pursuant to the Code or any provision of Federal,
state or local or non-U.S. tax law) with respect to such Member or as a result of such Member’s status as a Member hereunder. All
amounts withheld pursuant to the Code or any provision of tax laws with respect to any payment or distribution to the Members from the
Company shall be treated as amounts distributed to the Member or Members subject to such withholding obligation in accordance with this
Agreement and, accordingly, shall be credited to each Member as if such Member had received such distribution in accordance with Section
5.3. To the extent that such payment exceeds the cash distribution that such Member would have received but for such withholding, the
Board shall notify such Member as to the amount of such excess and such Member shall make a prompt payment to the Company of such amount
by wire transfer.

 

Article
6

Obligations of the MEmbers

 

6.1
Obligations of the Members. Each Member covenants and agrees to perform the obligations set forth under each such Member’s
name on Exhibit C attached hereto.

 

6.2
Force Majeure. No party shall be deemed to be in default under this Agreement or be held liable or responsible for any
delay or failure to fulfill any obligation hereunder, so long as and to the extent to which any delay or failure in the fulfillment of
such obligation is prevented, frustrated, hindered or delayed as a consequence of the occurrence of a Force Majeure; provided,
however, that the occurrence of a Force Majeure shall not excuse such party from its obligations but merely suspend the
performance of the obligations under this Agreement; and provided, further, that a party claiming the benefit of a Force
Majeure, shall, as soon as reasonably practicable after the occurrence of any such event, provide written notice to the other parties
of the nature and extent of any such Force Majeure; and use commercially reasonable efforts to resume performance under this Agreement
as soon as reasonably practicable.

 

Article
7

MANAGEMENT OF COMPANY

 

7.1
Management by the Board. Except for situations in which the approval of one or more Members is expressly required by this Agreement
or by non-waivable provisions of Applicable Law, the powers of the Company shall be exercised by or under the authority of, and the business
and affairs of the Company shall be managed under the direction of the Board. Except as expressly set forth in Sections 7.3 and
7.4, the Board may make all decisions and take all actions for the Company by majority vote.

 

7.2
Initial Board . The initial Board shall consist of five (5) managers (each, a “Manager”), of which two
(2) Managers shall be appointed by INVO (the “INVO Managers”) and three (3) Managers shall be appointed by
Provider (the “Provider Managers”). Any future increase in the number of Managers on the Board shall be subject
to the above ratio. The following persons shall serve as the first Board of the Company:

 

(a)
Andrea Goren, as an INVO Manager;

 

    	-9-

    	 

    

 

(b)
Chris Myer, as an INVO Manager;

 

(c)
Sue Ellen Carpenter, M.D., as a Provider Manager;

 

(d)
Daniel Carpenter, as a Provider Manager; and

 

(e)
Richard Carpenter, as a Provider Manager.

 

7.3
Actions Requiring Unanimous Member Approval. Notwithstanding anything to the contrary herein or in that certain Joint Venture
Agreement of the Company (the “JV Agreement”), for so long as the Members own any Units in the Company, neither
the Board nor the Company, directly or indirectly, shall take any of the following actions without the affirmative vote of all of the
Members to:

 

(a)
effect any merger, consolidation, recapitalization or reorganization involving the Company;

 

(b)
make any disposition of all or substantially all of the assets of the Company;

 

(c)
effect any Company Change of Control, except as otherwise permitted in Article 8 hereof;

 

(d)
effect a Liquidation;

 

(e)
effect any amendment or modification to or change in this Agreement, the Certificate of Formation of the Company, the JV Agreement or
other similar governing documents of the Company, or the authorization or creation of any Units (except those issued hereunder);

 

(f)
issue any new Units or any other equity securities of the Company, or enter into or issue any instrument, agreement or item convertible
into Units or any other equity securities of the Company, to any other Person;

 

(g)
issue or authorize any options to purchase equity securities of the Company containing acceleration of vesting provisions (other than
upon a Company Change of Control);

 

(h)
issue additional Units or any other equity securities of the Company, or enter into or issue any instrument, agreement or item convertible
into Units or any other equity securities of the Company, to a Party, except as otherwise authorized by this Agreement;

 

(i)
require, request or receive additional Capital Contributions for the benefit of the Company;

 

(j)
take any action the result of which is the redemption or repurchase of any Units or any other class or series of equity of the Company;

 

(k)
change the authorized size of, or powers of, the Board;

 

    	-10-

    	 

    

 

(l)
effect any acquisition by the Company of any interest in another Person (whether by purchase of stock, assets or otherwise) in an amount
greater than One Hundred Thousand Dollars ($100,000) dollars;

 

(m)
other than in the Ordinary Course of Business, except as related cause the Company to incur any indebtedness;

 

(n)
cause the Company to incur any aggregate indebtedness in excess of One Hundred Thousand Dollars ($100,000) dollars whether or not in
the Ordinary Course of Business;

 

(o)
change the tax status of the Company or make any tax election;

 

(p)
create any new Subsidiary;

 

(q)
enter into, approve or consent to any settlement of litigation or consent decree that could or would impose any financial liability or
obligation on a Party, or could or would impose on the Company and/or any Party any operational restriction or limitation of any nature
(including, but not limited to, reporting, monitoring, changes in operations or imposition of any compliance or corrective action plan);
and

 

(r)
enter into any binding agreement to take any of the foregoing actions.

 

7.4
Actions Requiring Super-Majority Approval. Notwithstanding anything to the contrary herein or in the JV Agreement, for so long
as the Members own any Units in the Company, the Company, directly or indirectly, shall not take any of the following actions without
the affirmative vote of at least eighty percent (80%) of the Managers, including at least one (1) INVO Manager (“Super-Majority
Approval”):

 

(a)
make any amendments to, or any other changes to, the Business Plan (as defined in Section 7.9);

 

(b)
borrowing other than normal credit in the Ordinary Course of Business;

 

(c)
grant any liens, on any property of the Company, outside the Ordinary Course of Business;

 

(d)
make any loans, guarantees or indemnification to Managers or third parties, other than as authorized by this Agreement;

 

(e)
enter into or amend any related party agreement with a Member or Manager or their family or Affiliates, other than on customary commercial
terms negotiated at arms’ length;

 

(f)
expand the business of the Company beyond the State of Georgia or effect any change in, addition to, supplementation or modification
of the business of the Company;

 

(g)
make any capital expenditure or distribution of assets which exceed $100,000 individually or in the aggregate in a fiscal year, unless
approved in the Business Plan;

 

(h)
enter into any agreements outside of Company’s normal course of business which provide for payments or assumption of liabilities
in excess of $100,000 unless specifically approved in the Business Plan

 

    	-11-

    	 

    

 

(i)
hire or terminate any key executive of the Company;

 

(j)
sell, assign, license, pledge or encumber the Company’s material technology or material, other than set forth in the Intellectual
Property Agreements;

 

(k)
enter into contracts or agreements for employment with any Person that include a liquidated damages provision or other severance arrangement;
or

 

(l)
make any material amendments to the Company’s internal policies.

 

7.5
Vacancies. In the event of any vacancies in the Board due to resignation, incapacity, disqualification or death of a director,
the Member who had originally appointed such Manager shall have the sole authority to appoint a replacement Manager.

 

7.6
No Fixed Term. Subject to Applicable Law, the Managers shall not be subject to any fixed term, rotation or retirement, unless
the Members desire to remove and replace their appointed Managers.

 

7.7
No Remuneration. The Managers shall not be remunerated for their appointment as Managers or for attending meetings of the Board.
The Company may, however, reimburse Managers the reasonable costs incurred for attending Board meetings, subject to any limitations prescribed
under Applicable Law.

 

7.8
No Liability for Appointment of Recommended Manager. No Member, nor any Affiliate of any Member, shall have any liability as a
result of appointing an individual as a Manager or any act or omission by such individual in her or his capacity as a Manager.

 

7.9
Business Plan. Within sixty (60) days from the date hereof, the Members shall use best efforts to work with the Board in preparing
a detailed business plan for the Company (the “Business Plan”). The Business Plan shall set out the objectives
and projections for the Company for the next five (5) years. The Business Plan shall include, but not be limited to cash flow projections,
operating budgets, sales forecast, business development, marketing and strategy plans, and start-up funding needs of the Company.

 

7.10
Meetings; Voting. The Board shall meet at least once every calendar quarter. Quorum for all Board meetings shall be three (3)
Managers; provided, however, that no quorum shall be present, and no meeting of the Board shall be considered to be validly
held until and unless at least one (1) INVO Manager and one (1) Provider Manager are present. Meetings of the Board may be held at such
place or places as shall be determined from time to time by resolution of the Board. At all meetings of the Board, business shall be
transacted in such order as shall from time to time be determined by resolution of the Board. All Board meetings shall be chaired by
a Manager appointed by the Board. All decisions of the Board shall be taken by majority vote, subject to the following. The Managers
present at the meeting, in the aggregate, will have a vote equal to the ownership percentage of the Member (and such Members’ permitted
transferees) who appointed such Manager as of the date of the vote (divided equally among such Managers present at the meeting). Subject
to the relevant provisions of the Act, any action permitted or required to be taken at a meeting of the Board may be taken without a
meeting, without prior notice and without a vote if a consent or consents in writing setting forth the action so taken are signed by
the Managers having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting.

 

7.11
Officers. In addition to the Board, the Members shall mutually agree and appoint the following officers (who may or may not be
Managers) for the day-to-day administration and operations of the Company on such terms and conditions as may be mutually agreed; provided
however that such officers shall always be subordinate to the Board and shall function under the overall supervision of the Board:

 

(a)
a Chief Executive Officer;

 

    	-12-

    	 

    

 

(b)
a Chief Financial Officer; and

 

(c)
such other officers as may be required or considered necessary by the Members.

 

7.12
Books and Records; Retaining Auditors and Accountants. The Board and the Members shall ensure that the Company (i) maintains proper
and transparent books of accounts as required by Applicable Law that accurately reflect the true financial position of the Company and
(ii) works with INVO to ensure that Company financial statements properly meet INVO’s public company reporting requirements and
timelines. The Company shall provide the Members with quarterly financial statements prepared in accordance with U.S. generally accepted
accounting principles. Upon written request and provided that the Ordinary Course of Business of the company would not be unreasonably
disrupted, the Board and the Members shall have access to inspect the books of account of the Company from time to time and receive periodic
business and financial reports of the Company.

 

7.13
Compliance with Law. The Members shall ensure that the Company (i) remains in full compliance with all Applicable Laws at all
times (including all data protection, data privacy and data storage laws), (ii) carries on its business to the highest medical and ethical
standards as per Applicable Law and (iii) for these purposes obtains all necessary and required registrations, licenses or permits to
conduct its business.

 

7.14
Duties of the Managers and the Members; Limitation of Liability; Certain Restrictive Covenants.

 

(a)
Notwithstanding any other provision of this Agreement, except as expressly provided pursuant to Section 7.14(b) through Section
7.14(d), this Agreement is not intended to, and does not, create or impose on the Managers or the Members any fiduciary duty, to
the Company or any other Member, in each case, other than the duty to act in good faith and exercise commercially reasonable judgment,
in complying with contractual obligations applicable in this Agreement in accordance with Section 18-1101(e) of the Act. Each Member
hereby covenants not to assert, to the maximum extent permitted by law, any and all rights and claims (or to collect against any such
claims asserted by others) that it, she or he may otherwise have against any Manager or any other Member, as applicable, as a result
of any claims of breach of fiduciary duties. The provisions of this Agreement, to the extent that they expressly restrict or modify the
duties (fiduciary or otherwise) and liabilities of a Manager or a Member otherwise existing at law or in equity, are agreed by the Company
and the Members to modify such other duties (fiduciary or otherwise) and liabilities of such Members and the Managers.

 

(b)
Each Member and each Manager agrees that, for so long as such Person holds any interest (directly or indirectly) in the Company (the
“Restricted Period”), such Person shall not, and shall cause its direct and indirect equity holders (excluding
any of INVO Bioscience’s public shareholders), partners, managers, employees, consultants, agents and Affiliates to not, without
the express written consent of the Company, directly or indirectly, engage in any activity which is competitive with the business, or
participate or invest in, or provide or facilitate the provision of financing to, or assist (whether as owner, part-owner, shareholder,
member, partner, director, officer, trustee, executive, agent or consultant, or in any other capacity), any Person in Georgia (the “Restricted
Area”) other than the Company, including any such Person involving, or which is, a family member of such Member or Manager,
whose business, activities, products or services are competitive with the Company’s business, during the Restricted Period (any
such Person or business, a “Competitor”). Notwithstanding the foregoing, no Member or Manager shall be prohibited
by this Section 7.14(b) from making a passive investment in any enterprise the shares of which are publicly traded if such investment
constitutes less than one percent (1%) of the equity of such enterprise. Nothing in this Section 7.14(b) is intended to, nor will
it restrict, Provider’s ability to exercise its rights under Article 8.

 

    	-13-

    	 

    

 

(c)
Each Member (on behalf of itself and its Affiliates) and each Manager agrees that, during the applicable Restricted Period, such Person
shall not, and shall cause its direct and indirect equity holders, partners, managers, employees, consultants, agents and Affiliates
to not, without the express written consent of the Company, directly or indirectly, solicit, contact, or attempt to solicit or contact,
the Company’s current or prospective customers and suppliers with whom such Member or Manager interacted, or from or about whom
such Member or Manager received Confidential Information (the “Customers and Suppliers”), for the purpose of
offering or accepting goods or services in the Restricted Area that are competitive with those offered by the Company, on behalf of any
Person other than the Company or any of its Subsidiaries, or otherwise adversely and intentionally interfere with the relationship between
the LLC or any of its Subsidiaries and any of their Customers and Suppliers.

 

(d)
Each Member and each Manager acknowledges that the purpose of the restrictions contained in this Section 7.14 are to protect the
Company’s legitimate business interests, relationships between the Company and its or their respective clients and customers, Confidential
Information, workforce stability, and business goodwill; in view of the nature of the Company’s business, these restrictions are
reasonable and necessary to protect these Company interests and in light of the Confidential Information provided or to be provided to
such Member and the Managers and the additional consideration provided under this Agreement; and any violation of this Agreement would
result in irreparable injury to the Company. In the event of a breach by any Member or any Manager of any provision of this 7.14, the
Company shall, in addition to any other legal remedies available, be entitled to a temporary restraining order and injunctive relief
restraining such applicable Member or Manager from the commission of any such breach, and, if successful, to recover the Company’s
reasonable attorneys’ fees, costs, and expenses related to the breach. The existence of any claim or cause of action by any Member,
any Manager or any of their respective Affiliates against the Company, whether predicated on this Agreement or otherwise, shall not constitute
a defense to the enforcement by the Company of the restrictive covenants contained in this Section 7.14 or to injunctive relief.

 

7.15
Tax Matters. The Company shall cause to be prepared and filed all necessary federal, state and local income tax returns for the
Company and shall use all commercially reasonably efforts to furnish to each Member a Schedule K-1 within ninety (90) days of, or, if
later, as soon as reasonably practicable following, the close of the Company’s taxable year. The Company shall make any elections
the Board may deem appropriate and in the best interests of the Members. Each Member shall furnish to the Company all pertinent information
in the Member’s possession relating to Company operations that is necessary to enable the Company’s income tax returns to
be prepared and filed.

 

Article
8

Transfer Restrictions; RIGHT OF FIRST REFUSAL; Put Option; Drag-Along AND TAG-ALONG RightS

 

8.1
Restriction on Transfer. Except as otherwise specifically provided herein, no Member holding Units shall sell, exchange, transfer
(by gift or otherwise), assign, distribute, pledge, create a security interest, lien or trust with respect to, or otherwise dispose of
such Units owned by such Member or any interest in or option on or based on the value of such Units (any of the foregoing being referred
to as a “Transfer”) without the prior written consent of each other Member. Any attempted Transfer not permitted
by and in compliance with this Article 8 shall be null and void, and the Company shall not recognize the attempted purchaser,
assignee, or transferee for any purpose whatsoever, nor record any such event on its books or treat any such transferee as the owner
of such Units for any purpose, and the Member attempting such Transfer shall have breached this Agreement for which the Company and shall
have all remedies available for breach of contract. The admission of a substitute Member shall not result in the release of the Member
who assigned the Unit from any liability that such Member may have to the Company. Any Transfer permitted by this Agreement shall be
termed a “Permitted Transfer” and the transferee of any Permitted Transfer shall be termed a “Permitted
Transferee.”

 

    	-14-

    	 

    

 

8.2
Effective Date and Requirements of Transfer.

 

(i)
Any valid Transfer of a Member’s Units, or part thereof, pursuant to the provisions of this Agreement, shall be effective as of
the close of business on the day in which such Transfer occurs (including fulfillment of all conditions and requirements with respect
thereto). The Company shall, from the effective date of such Transfer, thereafter make all further distributions, on account of the Units
(or part thereof) so assigned to the Permitted Transferee of such interest, or part thereof.

 

(ii)
Every Transfer permitted hereunder shall be subject to the following requirements (in addition to any other requirements contained in
this Agreement):

 

A.
If not already a Member, the transferee shall execute a counterpart to this Agreement thereby agreeing to be bound by all the terms and
conditions of this Agreement;

 

B.
The transferee shall establish that the proposed Transfer will not cause or result in a breach of any agreement binding upon the Company
or any violation of Applicable Law, including without limitation, federal or state securities laws, and that the proposed Transfer would
not cause or require (A) the Company to be an investment company as defined in the Investment Company Act of 1940, as amended or (B)
the registration of the Company’s securities under federal securities laws; and

 

C.
The transferee shall establish to the satisfaction of the Board that the proposed Transfer would not adversely affect the classification
of the Company as a partnership for federal or state tax purposes or otherwise have a substantial adverse effect with respect to federal
income taxes payable by the Company.

 

(iii)
If any Member who proposes to Transfer any Units (or if such Member is a disregarded entity for U.S. federal income tax purposes, the
Member’s owner) is not a “United States person” as defined in Section 7701(a)(30) of the Code, then such transferor
and transferee shall jointly provide to the Company written proof reasonably satisfactory to the Board that any applicable withholding
tax that may be imposed on such transfer (including pursuant to Sections 864 and 1446 of the Code) and any related tax returns or forms
that are required to be filed, have been, or will be, timely paid and filed, as applicable.

 

8.3
Duty of Provider. For any transaction contemplated by this Article 8, for at least one hundred eighty days (180) days following
the Members’ consent to a Permitted Transfer, delivery of a Transfer Notice, the date the Put Notice is received by INVO, or the
election of commencement of a Sale of the Company pursuant to the terms hereof, Provider shall ensure that Dr. Carpenter uses commercially
reasonable efforts to perform any services reasonably requested by INVO that are necessary or appropriate to transition the provision
of clinical management and operations for the INVO Clinic, and to provide and/or assist with the provision of any training reasonably
required to any other licensed providers designated by INVO. Any failure to comply with the terms of this Section 8.3 will constitute
a material breach of this Agreement.

 

    	-15-

    	 

    

 

8.4
Put Rights.

 

(i)
Provider Put Option

 

A.
If (1) at any time during the period commencing on the second (2nd) anniversary of the Effective Date and ending on the sixth
(6th) anniversary of the Effective Date (the “Initial Exercise Period”), the Company’s revenues
deviate from those projected in the Business Plan for a given calendar year by more than fifty percent (50%), or (2) at any time following
the sixth (6th) anniversary of the Effective Date (the “Extended Exercise Period” and, together
with the Initial Exercise Period, the “Exercise Period”), Provider shall have an irrevocable option (the “Put
Option”), exercisable in whole but not in part, to sell all but not less than all, of the Provider Units to INVO for the
Purchase Price (as defined in Section 8.4(iii)) and on the terms set forth in this Section 8.4 (the “Put Transaction”).
Provider shall only be permitted to exercise its Put Option one time during the Initial Exercise Period, and shall be permitted to exercise
the Put Option only once in any subsequent three (3) year period during the Extended Exercise Period.

 

B.
During the Exercise Period, Provider may exercise the Put Option by delivering an irrevocable written notice to INVO (the “Put
Notice”), stating that (A) Provider is exercising the Put Option and (B) when the purchase and sale of the Provider Units
is anticipated to occur in accordance herewith, such date being subject to adjustment as agreed to in writing by Provider and INVO.

 

C.
In the event Provider exercises the Put Option, and in consideration of the sale by Provider to INVO of the Provider Units to INVO, INVO
shall pay to Provider an aggregate cash purchase price for the Provider Units equal to the Purchase Price.

 

D.
Notwithstanding anything to the contrary contained herein, so long as in compliance with Applicable Law, INVO shall have the right during
the Exercise Period, in its sole discretion, to assign all or any portion of its rights and obligations with respect to the Put Option
to any third-party designee or designees. Notwithstanding the foregoing, INVO shall remain liable for the failure by a third-party designee
to consummate the Put Transaction and to pay its portion of the Purchase Price. Any reference to INVO pertaining to a Put Transaction
in this Section 8.4 (other than any reference to INVO’s guarantee of its assignees’ performances with respect thereto)
shall be deemed to refer to INVO (if it holds an unassigned interest in the Call Option) and its assignees of any portion of its rights
and obligations with respect to the Put Option under this Section 8.4, acting jointly.

 

(ii)
Put Option Procedures.

 

A.
The closing of a Put Transaction (the “Closing”) shall take place on a mutually agreed date upon the electronic
exchange of PDF signature pages promptly after the Purchase Price is finally determined in accordance with this Section 8.4, but
in any event not later than the later of (i) thirty (30) days following such final determination and (ii) one hundred and twenty (120)
days from delivery of the Put Notice or Call Notice, as the case may be (which period may be extended upon the written consent of INVO
and Provider.)

 

B.
At the Closing, (A) Provider, INVO and any assignees of INVO shall execute and deliver a customary secondary purchase agreement for the
sale and purchase of the Provider Units (the “Purchase Agreement”), together with all other agreements and
documents required to be delivered at such Closing pursuant to the Purchase Agreement, (B) Provider shall sell and transfer to INVO and/or
any assignees all of its respective right, title and interest in and to all of the Provider Units, and INVO and/or any assignees shall
purchase all of such Provider Units, free and clear of any liens or encumbrances (other than those provided for or permitted in this
Agreement or arising under Applicable Law or under any indebtedness agreement of the Company), at an aggregate cash purchase price equal
to the Purchase Price, (C) Provider shall deliver to INVO and/or any assignees the certificates (if any) representing all of the Provider
Units accompanied by duly executed transfer powers, and (D) INVO and/or any assignees shall deliver all amounts owed to Provider at the
Closing by wire transfer of immediately available funds to an account designated in writing by Provider, as determined pursuant to this
Section 8.4 and the Purchase Agreement.

 

    	-16-

    	 

    

 

C.
Notwithstanding anything to the contrary set forth in this Agreement, unless otherwise waived in writing, the obligations of INVO and
Provider to consummate the Put Transaction shall be subject to and conditioned upon (A) the receipt of all material, required approvals
from, and the delivery of all material, required notices to, any Governmental Authority, and (B) the receipt of all material, required
approvals from, and the delivery of all material, required notices to, any Person with respect to whom the Company has a contractual
obligation receive approval or deliver notice in connection with the consummation of such transaction. INVO and Provider shall use commercially
reasonable efforts (and shall cause the Company to use its commercially reasonable efforts) to promptly obtain and provide any such approvals
and provide any required notices, as promptly as reasonably practicable after exercise of the Put Option.

 

(iii)
Determination of Purchase Price.

 

A.
Upon receipt of the Put Notice, INVO and Provider jointly will engage an independent third party experienced in the provision of fair
market valuations (the “Independent Valuator”) to determine the fair market value of the Provider Units to
be sold subject to the Put Transaction (the “Purchase Agreement”), or, if they cannot so mutually agree, they
shall each promptly (and in any event within five (5) days) select an Independent Valuator, and the two Independent Valuators so selected
shall select the Independent Valuator to perform the valuations; provided, however, that if one party fails to so select
such firm, then the firm selected by the other party shall be the Independent Valuator). INVO and Provider shall jointly retain and instruct
the Independent Valuator to prepare and deliver a written report to INVO and Provider promptly, but in any event within twenty (20) days,
setting forth the Independent Valuator’s calculation of the fair market value of the Provider Units as of the date the Put Notice
is given, and the resulting amount of the Purchase Price. INVO and Provider shall, and shall cause their respective representatives to,
cooperate with the Independent Valuator. The Independent Valuator’s determinations shall be based solely on the submissions by
INVO and Provider (and not by independent review of the financial information and operations of the Company), this Agreement, and the
applicable defined terms set forth in this Agreement. The Independent Valuator’s determination of such amount will be final, conclusive
and binding upon all parties hereto and not subject to review by a court or other tribunal but upon which a judgment may be entered into
by a court of competent jurisdiction.

 

B.
The costs, expenses and fees of the Independent Valuator shall be allocated to and borne by the Company.

 

C.
The foregoing procedures in this Section 8.4(iii) shall be used for all purposes relating to the determination and payment of
the Purchase Price pursuant to this Agreement and the Purchase Agreement.

 

(iv)
Failure to Consummate a Put Transaction.

 

In
the event that the Put Option is exercised by Provider and, other than as a result of Provider’s actions or inactions, the Put
Transaction is not consummated within the time period for the applicable Closing in accordance with Section 8.4(ii)A (a “Put
Non-Sale Event”), then Provider shall have the right, but not the obligation, to (1) sell its Units to a third party transferee
in exchange for a purchase price no less than the fair market value of its Units, as determined by an Independent Valuator pursuant to
the procedure set forth in Section 8.4(iii) but without further approval or consent of INVO, or (2) commence a Sale
of the Company pursuant to Section 8.5. If Provider elects to transfer its units to a third party transferee, then Provider must
deliver a notice of the proposed transfer (“Transfer Notice”) to Company and INVO not later than forty-five
(45) days prior to the consummation of such proposed transaction, which will include a description of its material terms and conditions
(including price and form of consideration) and the identity of the Proposed Transferee. Such transfer must be completed within ninety
(90) days of delivery of the Transfer Notice.

 

    	-17-

    	 

    

 

(v)
Termination; Surviving Obligations. The rights and obligations of INVO and Provider under this Section 8.4 shall automatically
terminate upon the consummation of the Closing or a Change of Control.

 

8.5
Sale of the Company; Drag-Along and Tag-Along Rights.

 

(i)
Definitions. A “Sale of the Company” means a transaction or series of related transactions in which
a Person, or a group of related Persons, that is or are not Affiliates of the Company, acquires from the Members an amount of Units representing
more than fifty percent (50%) of the outstanding voting power of the Company (a “Unit Sale”).

 

(ii)
Actions to be Taken. In the event that Provider is permitted to engage in a Sale of the Company pursuant to Section 8.4(iii)
hereof, each Member hereby agrees:

 

A.
if such transaction requires Member approval, with respect to all Units that such Member owns or over which such Member otherwise exercises
voting power, to vote (in person, by proxy or by action by written consent, as applicable) all Units in favor of, and adopt, such Sale
of the Company (together with any related amendment to this Agreement required in order to implement such Sale of the Company) and to
vote in opposition to any and all other proposals that could reasonably be expected to delay or impair the ability of the Company to
consummate such Sale of the Company;

 

B.
if such transaction is a Unit Sale, to sell the same proportion of Units beneficially held by INVO as are being sold by Provider to the
Person to whom it proposes to sell its Units, and, except as permitted in Section 8.5(iii) on the same terms and conditions as
Provider;

 

C.
to execute and deliver all related documentation and take such other action in support of the Sale of the Company as shall reasonably
be requested by the Company or the Provider in order to carry out the terms and provisions of this Section 8.5(ii), including,
without limitation, executing and delivering instruments of conveyance and transfer, and any purchase agreement, merger agreement, indemnity
agreement, escrow agreement, consent, waiver, Governmental Authority filing, and any other similar or related documents necessary to
consummate such Sale of the Company;

 

D.
not to deposit, and to cause their Affiliates not to deposit, except as provided in this Agreement, any Units owned by such party or
Affiliate in a voting trust or subject any Units to any arrangement or agreement with respect to the voting of such Units, unless specifically
requested to do so by the acquirer in connection with the Sale of the Company;

 

E.
to refrain from exercising any dissenters’ rights or rights of appraisal under Applicable Law at any time with respect to such
Sale of the Company; and

 

    	-18-

    	 

    

 

F.
if the consideration to be paid in exchange for the Units pursuant to this Section 8.5 includes any securities and due receipt
thereof by any Member would require under Applicable Law (x) the registration or qualification of such securities or of any person as
a broker or dealer or agent with respect to such securities or (y) the provision to any Member of any information other than such information
as a prudent issuer would generally furnish in an offering made solely to “accredited investors” as defined in Regulation
D promulgated under the Securities Act, the Company may cause to be paid to any such Member in lieu thereof, against surrender of the
Units which would have otherwise been sold by such Member, an amount in cash equal to the fair value (as determined in good faith by
the Company) of the securities which such Member would otherwise receive as of the date of the issuance of such securities in exchange
for the Units.

 

(iii)
Exceptions. Notwithstanding the foregoing, a Member will not be required to comply with the terms of Section 8.5(ii) above
in connection with any proposed Sale of the Company (the “Proposed Sale”) unless:

 

A.
any representations and warranties to be made by such Member in connection with the Proposed Sale are limited to reasonable and customary
representations and warranties for a company of similar size and type of business, including those related to (x) the Member’s
related to authority, ownership and the ability to convey title to such Units, including but not limited to representations and warranties
that (A) the Member holds all right, title and interest in and to the Units such Member purports to hold, free and clear of all liens
and encumbrances, (B) the obligations of the Member in connection with the Proposed Sale have been duly authorized, if applicable, (C)
the documents to be entered into by the Member have been duly executed by the Member and delivered to the acquirer and are enforceable
against the Member in accordance with their respective terms and (D) neither the execution and delivery of documents to be entered into
in connection with the Proposed Sale, nor the performance of the Member’s obligations thereunder, will cause a breach or violation
of the terms of any agreement or Applicable Law, and (y) the Company’s provision of management services to Provider;

 

B.
the Member shall not be liable for the inaccuracy of any representation or warranty made by any other Person in connection with the Proposed
Sale, other than for the inaccuracy of any representation or warranty made by the Company in connection with the Proposed Sale (except
to the extent that funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the
Company as well as breach by any Member of any of identical representations, warranties and covenants provided by all Members);

 

C.
the liability for indemnification, if any, of such Member in the Proposed Sale and for the inaccuracy of any representations and warranties
made by the Company in connection with such Proposed Sale, is several and not joint with any other Person (except to the extent that
funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Company), and is pro
rata in proportion to the amount of consideration paid to such Member in connection with such Proposed Sale (in accordance with the
provisions of this Agreement related to the allocation of the escrow);

 

D.
the liability for indemnification shall be limited to such Member’s pro rata share (determined based on the respective proceeds
payable to each Member in connection with such Proposed Sale in accordance with the provisions of this Agreement) of a negotiated aggregate
indemnification amount that applies equally to all Members but that in no event exceeds the amount of consideration actually paid to
such Member in connection with such Proposed Sale, except with respect to claims of fraud by such Member, the liability for which need
not be limited as to such Member;

 

E.
upon the consummation of the Proposed Sale: (A) except as provided in Section 8.5(ii)F, each holder of each class or series of
Units will receive the same form of consideration for their Units of such class or series as is received by other holders in respect
of their Units of such same class or series of Units; and (B) the aggregate consideration receivable by all holders of Units shall be
allocated among the Members in accordance with this Agreement as if such consideration were distributed to the Members pursuant thereto;
and

 

    	-19-

    	 

    

 

F.
except as provided in Section 8.5(ii)F, subject to clause (v) above, requiring the same form of consideration to be available
to the holders of any single class or series of Units, if any holders of any Units are given an option as to the form and amount of consideration
to be received as a result of the Proposed Sale, all holders of such Units will be given the same option.

 

Article
9

LIABILITY; Tax Matters Partner

 

9.1
Liability. Except as otherwise provided by the Act, the debts, obligations and liabilities of the Company, whether arising in
contract, tort or otherwise, shall be solely the debts, obligations and liabilities of the Company, and no Covered Person shall be obligated
personally for any such debt, obligation or liability of the Company solely by reason of being a Covered Person.

 

9.2
Tax Matters Partner. The Board shall designate a Member to act as “Partnership Representative” of the
Company for purposes of the Partnership Audit Rules shall have the power and authority, subject to the review and control of the Board,
to manage and control, on behalf of the Company, any administrative proceeding involving the Company with the Internal Revenue Service
or other taxing authority relating to the determination of any item of Company income, gain, loss, deduction or credit for federal income
tax purposes. Each Member expressly agrees to consents to such designation and agrees that, upon the reasonable request of the Partnership
Representative, it will execute, acknowledge, deliver, file and record at the appropriate public offices such documents as may be necessary
or appropriate to effect such consent. Notwithstanding anything in this Agreement to the contrary, each Member shall be liable for and,
promptly upon demand by the Partnership Representative, pay to the Company such Member’s share of any imputed underpayment, as
determined by the Partnership Representative, and any interest and penalties relating thereto imposed on the Company as a result of any
partnership adjustment or other proceeding with substantially similar effect under Partnership Audit Rules. The liability and obligation
of a Member under this Section 9.2 shall survive any sale, exchange, liquidation, retirement or other disposition of such Member’s
interest in the Company.

 

Article
10

DISSOLUTION, LIQUIDATION AND TERMINATION

 

10.1
No Dissolution. Only the written agreement of each Member or the events set forth in Section 10.2 shall cause the termination
of this Agreement or dissolution of the Company. The Company shall not be dissolved by the admission of additional or substitute Members
in accordance with the terms of this Agreement.

 

10.2
Events Causing Dissolution. This Agreement may be terminated and the Company shall be dissolved at the option of any Member upon
occurrence of any of the following (each, an “Event of Default”):

 

(a)
the determination by all of the Members that the Company should be dissolved.

 

(b)
the sale or distribution by the Company of all or substantially all of its assets;

 

    	-20-

    	 

    

 

(c)
any Member materially defaults in the performance of any of the covenants, terms or conditions of this Agreement or any Ancillary Agreement,
and fails to cure such default to the reasonable satisfaction of the other Members (in the case of this Agreement) or any Members or
Affiliates of Members that are party to any Ancillary Agreement (in the case of any Ancillary Agreement) within thirty (30) days after
receipt of notice in writing from the Company or any other Member of such default;

 

(d)
any Member suffers or permits the appointment of a receiver for its business or assets, or avails itself of or become subject to any
bankruptcy or insolvency proceeding under any statute of any governing authority relating to insolvency or the protection of rights of
creditors;

 

(e)
the occurrence and continuation of any Force Majeure for a period of six (6) months; or

 

(f)
the entry of a decree of judicial dissolution or the administrative dissolution of the Company as provided in the Act.

 

Any
other provision of this Agreement to the contrary notwithstanding, no withdrawal, assignment, removal, bankruptcy except as required
by Applicable Law, insolvency except as required by Applicable Law, death, incompetency, termination, dissolution or distribution with
respect to any Member or any Unit will effect a dissolution of the Company.

 

10.3
Effect of Termination. Upon the termination of this Agreement for any reason:

 

(a)
any Ancillary Agreement or other agreement, license, approval or consent granted to the Company by INVO and/or entered into by the Parties
shall automatically be terminated (except for such terms which shall survive the termination of this Agreement or dissolution of the
Company pursuant to such agreement);

 

(b)
each Member and the Company shall promptly return to the owner and (if also applicable) erase or destroy all Confidential Information,
including all copies, notes, drawings, photocopies, written, audio or photographic records or other records in any form, relating to
the Confidential Information in their possession or control; provided that a party may retain Confidential Information solely
to the extent required under Applicable Law; and

 

(c)
the Company shall be dissolved in accordance with the Act after all of the assets of the Company, after payment of or due provision for
all debts, liabilities and obligations of the Company, have been distributed as provided in Section 5.6.

 

10.4
Claims of the Members. The Members and former Members shall look solely to the Company’s assets for the return of their
Contributions, and if the assets of the Company remaining after payment of or due provision for all debts, liabilities and obligations
of the Company are insufficient to return such Contributions, the Members and former Members shall have no recourse against the Company
or any other Member with respect to such Contributions.

 

Article
11

CONFIDENTIALITY

 

11.1
Company Confidential Information. The Members covenant, warrant and undertake to keep and to cause the Company to keep all Confidential
Information confidential and not use, disclose, divulge, make known, publish, communicate, reproduce or transmit in any manner, any Confidential
Information, in whole or in part; directly or indirectly, during the term of or at any time forever after termination of this Agreement,
either for their own benefit or for the benefit of others. The Members shall cause their Affiliates and each of their Affiliates’
and the Company’s officers, managers, employees, agents, contractors, sub-contractors, consultants, or any persons acting of any
of their behalf, to keep all Confidential Information confidential and not use, disclose, divulge, make known, publish, communicate,
reproduce or transmit in any manner any Confidential Information, in whole or in part, directly or indirectly, during the term of or
at any time forever after termination of this Agreement, either for their own benefit or for the benefit of others.

 

    	-21-

    	 

    

 

11.2
Member Confidential Information. Each of the Members undertakes to keep confidential all information (written or oral) concerning
the business and affairs of any other Member that it shall have obtained or received as a result of the discussions leading up to or
the entering into of this Agreement or in the course of giving effect to this Agreement.

 

11.3
Exceptions. The obligations for confidentiality set forth above shall not apply if the Confidential Information:

 

(a)
is publicly known or present in the public domain through no fault, failure, wrongful act or negligence of the receiving party, its Affiliates
or any of their respective officers, managers, employees, agents, contractors, sub-contractors, consultants, partners, or any persons
acting on any of their behalf;

 

(b)
is required to be disclosed pursuant to a valid order or direction of a proper court of competent jurisdiction or a government authority;
provided, however, that the receiving party will use its best efforts to minimize the disclosure of such information and
prior to disclosing the Confidential Information will notify the owner of the Confidential Information and will consult with and assist
the owner of such Confidential Information in obtaining a protective order prior to such disclosure; or

 

(c)
is required to be disclosed to a Member’s professional advisors (including a Member’s lawyers, auditors, accountants and
consultants); provided such advisor is bound in writing by confidentiality obligations no less restrictive than those applicable
to a Member, as set forth herein.

 

11.4
Irreparable Harm; Equitable Relief; Survival. The receiving party of any Confidential Information acknowledges and agrees that
its failure to comply with any of the provisions of this Article 11 may cause irrevocable harm to the disclosing Member and that
a remedy at law may not be an adequate remedy and that the disclosing Member may, in its sole discretion, obtain from a court having
proper jurisdiction an injunction, restraining order, specific performance or other equitable relief to enforce such provision. The disclosing
Member’s right to obtain such equitable relief will be in addition to any other remedy that it may have under Applicable Law including,
but not limited to, monetary damages. The provisions of this Article 11 and obligations of any receiving party shall survive the
termination of this Agreement and dissolution of the Company.

 

Article
12

Intellectual Property

 

12.1
Duties of the Company and the Members.

 

(a)
The Company and Provider shall promptly and fully notify INVO of any actual, threatened or suspected infringement of Intellectual Property
which comes to such party’s notice, and of any claim by any third party coming to such party’s notice that the use of the
INVO Technologies contemplated hereunder infringes any rights of any other person, and INVO
shall at the request of the Company, do all things as may be reasonably required to assist the Company in undertaking or resisting any
proceedings in relation to any such infringement or claim.

 

    	-22-

    	 

    

 

(b)
The Company and Provider shall take all such steps as INVO may reasonably request to assist INVO in maintaining the validity and enforceability
of the Intellectual Property during the term of this Agreement.

 

12.2
No Rights in Intellectual Property. Nothing in this Agreement shall give Provider or the Company any rights in respect of any
Intellectual Property (whether registered or not) used by the Company in relation to the INVO Technologies
or of the goodwill associated therewith, and each of Provider and the Company hereby acknowledge that, except as expressly provided
in this Agreement, Provider and the Company shall not acquire any rights in respect thereof and that all such rights and goodwill are
and shall remain vested in INVO as the case may be.

 

12.3
Use of Intellectual Property by Provider.

 

(a)
Provider shall not, and shall cause each of its Affiliates to not, register any Intellectual Property, including trademarks or trade
names so resembling the trademarks or trade names of INVO or so as to be likely to cause confusion or deception during the duration of
this Agreement and thereafter.

 

(b)
Provider shall not, and shall cause each of its Affiliates to not, authorize any third party to do any act which would or might invalidate
or be inconsistent with the Intellectual Property and shall not omit or authorize any third party to omit to do any act, which by its
omission would have that effect or character.

 

(c)
Provider shall not, and shall cause each of its Affiliates to not, during the term of this Agreement and for the five (5) year period
thereafter (whether as shareholder or as reseller, dealer, marketing affiliate, distributor, partner, consultant of any entity or pursuant
to any other similar relationship with any other entity), be engaged in the business of providing or reselling any goods using or resembling
any of the Intellectual Property related to INVO Technologies or any part thereof; provided,
however, that each Physician Employee shall be free to provide fertility treatment independently from the INVO Clinic and the
Provider subject to and upon her or his Physician Employment Agreement either (i) expiring or (ii) being terminated without cause by
the Company.

 

12.4
Use of Trademarks by the Company. All representations of INVO’s trademarks which the Company intends to use shall first
be submitted to INVO for approval (which shall not be unreasonably withheld). In addition, the Company shall not alter or remove any
of INVO’s trademarks affixed to any brochure or other material supplied by INVO and shall comply with all other guidelines communicated
by INVO concerning the use of INVO’s trademarks.

 

Article
13

DISPUTE RESOLUTION

 

13.1
Dispute Resolution. Each of (i) disputes between the Members as to the appropriate construction, enforcement and interpretation
of the provisions of the Agreement and (ii) any Board Deadlock shall be resolved in accordance with this Section 13.1. Notwithstanding
the foregoing, a deadlock among the Members shall not, in and of itself, constitute a dispute subject to resolution under this Section
13.1, unless the deadlock stems from a dispute regarding the interpretation of the terms or conditions of this Agreement.

 

    	-23-

    	 

    

 

(a)
If the dispute resolution process is invoked, representatives of each of INVO and Provider will meet informally within seven (7) days
after receipt of notice from the Member invoking the dispute resolution process, or, in the case of a Board Deadlock, any Manager, to
discuss the areas of disagreement and to negotiate in good faith regarding possible solutions.

 

(b)
If the informal discussions do not result in a resolution of the dispute then, INVO and Provider will name a neutral mediator. If such
parties are unable to agree on a single mediator within fourteen (14) days after receipt of notice invoking the dispute resolution process,
the mediator will be selected in accordance with the alternative dispute resolution process established by the American Health Lawyers
Association. The mediator will have no authority to impose a resolution, but will work with the disputants to reach a mutually acceptable
solution. All parties involved in the dispute will give the mediator their full cooperation and will participate in good faith in all
sessions convened by the mediator. The costs of engaging such mediator shall be borne by the Company, or, if the Company has insufficient
assets, equally by the Members.

 

(c)
Any dispute under that is not resolved by the informal meeting or mediation procedures set forth above shall be submitted to binding
arbitration in accordance with the procedures outlined in Section 13.2 below.

 

13.2
Arbitration. In the event a dispute is to be submitted to binding arbitration pursuant to Section 13.1(c), the below procedures
shall govern:

 

(a)
INVO shall appoint one (1) arbitrator, Provider shall appoint one (1) arbitrator, and the selected arbitrators shall jointly appoint
a third arbitrator (the “Independent Arbitrator”). The arbitrator appointed by a Member may be a Person
who has provided services (other than as an employee) to such Member. To the extent the arbitrators have any procedural issues in
conducting the arbitration, they shall defer to and rely upon the American Health Lawyers Dispute Resolution Process.

 

(b)
The arbitrators shall meet and the Members shall use commercially reasonable efforts to cause the arbitrators to provide a written resolution
of the disputed matter within thirty (30) days of their appointment in which at least two (2) of the arbitrators concur or to notify
the parties that no such concurrence has been reached. Such thirty (30) day period may be extended by agreement of the disputing Members.
The resolution of the arbitrators shall be binding upon the Members and the Board of Managers, absent manifest error, and if no such
resolution can be reached, each such party shall be entitled to pursue all remedies available to it at law or in equity with respect
to the dispute.

 

(c)
The Members may agree in writing to conduct the arbitration exclusively by the Independent Arbitrator.

 

(d)
At all times during the arbitration process, the Members agree to use reasonable efforts to continue to operate the Company in the Ordinary
Course of Business.

 

(e)
All costs and reasonable legal fees shall be awarded to the prevailing party in any arbitration or legal proceeding related to this Agreement.

 

(f)
The Members shall keep the arbitration proceedings and terms of any arbitration award confidential, except as may be necessary to enforce
the award.

 

    	-24-

    	 

    

 

Article
14

MISCELLANEOUS

 

14.1
Governing Law. This Agreement (including any claim or controversy arising out of or relating to this Agreement) shall be governed
by and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles that would result
in the application of any law other than the laws of the State of Delaware.

 

14.2
Submission to Jurisdiction; Waiver. Each party irrevocably agrees that any legal action or proceeding arising out of or relating
to this Agreement or for recognition and enforcement of any judgment in respect hereof brought by another party hereto or its successors
or assigns shall be brought and determined in the state or federal courts of the State of Delaware, as well as to the jurisdiction of
all courts to which an appeal may be taken from such courts, and each party hereby irrevocably submits with regard to any action or proceeding
for itself and in respect to its property, generally and unconditionally, to the exclusive jurisdiction of the aforesaid courts. Each
party hereto hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any action
or proceeding with respect to this Agreement, (a) any claim that it is not personally subject to the jurisdiction of the above-named
courts for any reason other than the failure to lawfully serve process, (b) that it or its property is exempt or immune from jurisdiction
of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment,
attachment in aid of execution of judgment, execution of judgment or otherwise), and (c) to the fullest extent permitted by Applicable
Law, that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action
or proceeding is improper and (iii) this Agreement or the subject matter hereof, may not be enforced in or by such courts.

 

14.3
Exclusivity. The Company agrees that it will operate the INVO Clinic as a dedicated INVO Technologies fertility clinic, and that
INVO shall be the exclusive supplier of such INVO Technologies (including any subsequent new product generations).

 

14.4
Fees and Expenses. Each party hereto shall bear its own legal and other fees and expenses in connection with the purchase of Units
and the preparation and entering into of this Agreement and the Ancillary Agreements.

 

14.5
Binding Effect. This Agreement shall be binding upon and inure to the benefit of all of the parties and, to the extent permitted
by this Agreement, their successors, legal representatives and assigns.

 

14.6
Notices. All demands, notices, requests, consents and other communications required or permitted under this Agreement shall be
in writing and shall be personally delivered or sent by electronic mail or facsimile machine (with a confirmation copy sent by one of
the other methods authorized in this Section 14.6), generally recognized receipted overnight courier (including FedEx) or U.S.
Postal Service overnight delivery service, or, deposited with the U.S. Postal Service mailed first class, registered or certified mail,
postage prepaid, to the addresses set forth on Exhibit B for any Member. Any change in such addresses shall be promptly communicated
in writing by each party hereto to each other party hereto.

 

14.7
Severability. If any part, term or provision of this Agreement is held to be illegal or unenforceable, the validity or enforceability
of the remainder of this Agreement shall not be affected, if such part, term or provision is severable from the rest of this Agreement,
without altering the essence of this Agreement. If such part, term or provision is not so severable, then the parties hereto shall negotiate
in good faith in order to agree to the terms of a mutually satisfactory replacement provision, achieving as nearly as possible the same
commercial effect of the provision so found to be invalid, illegal or unenforceable.

 

14.8
Counterparts; Facsimile Signatures. This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic
mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act
or other Applicable Law) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly
delivered and be valid and effective for all purposes.

 

14.9
Entire Agreement. This Agreement constitutes the entire agreement and understanding among the parties hereto with respect to the
subject matter hereof and supersedes all prior agreements and understandings, written or oral, relating to such subject matter.

 

14.10
Amendments. Except as otherwise specified herein, this Agreement may be amended or and the observance of any term hereof may be
waived (either generally or in a particular instance and either retroactively or prospectively) only by a written instrument executed
by the holders of a majority of the outstanding Units

 

14.11
Acknowledgments and Representations. Each Member hereby acknowledges and makes such representations and warranties related to
Company securities as are set forth on Exhibit D attached hereto.

 

[Signature
page follows.]

 

    	-25-

    	 

    

 

IN
WITNESS WHEREOF, this Limited Liability Company Agreement has been duly executed and delivered by the parties as of the date first written
above.

 

	 	COMPANY:
	 	Bloom
    INVO LLC
	 	 
	 	By:	/s/
    Sue Ellen Carpenter                               
	 	Name:	Sue
    Ellen Carpenter, M.D.
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	MEMBERS:
	 	 
	 	INVO
    Centers, LLC
	 	 
	 	By:	INVO
    Bioscience, Inc.
	 	Its:	Managing
    Member
	 	 	 
	 	By:	/s/
    Steven Shum
	 	Name:	Steven
    Shum
	 	Its:	Chief
    Executive Officer
	 	 	 
	 	INVO
    Centers, LLC

    5582 Broadcast Court

    Sarasota, Florida 342240

    Attention: Steven Shum

    Email: legal@invobio.com
	 	 
	 	Bloom
    Fertility, LLC
	 	 
	 	 	 
	 	By:	/s/
    Sue Ellen Carpenter
	 	Name:	Sue
    Ellen Carpenter, M.D.
	 	Title:	Managing
    Member
	 	 	 
	 	Bloom
    Fertility, LLC 

    987 Canton Street, Bldg. 14

    Roswell, GA, 30075

    Phone: 678-597-9933  Fax: 678-726-8183

    Attention: Sue Ellen Carpenter, M.D. 

    Email: sekcarpenter@mindspring.com

 

    	 

    	 

    

 

Exhibit
A

 

Definitions

 

“Act”
means the Delaware Limited Liability Company Act, as amended.

 

“Adjusted
Capital Account Deficit” means, with respect to the Capital Account of any Member as of the end of any Fiscal Period, the amount
by which the balance in such Capital Account is less than $0.00, after giving effect to the following adjustments:

 

(a)
Each Member’s Capital Account shall be increased by the amount, if any, such Member is obligated to contribute or is treated as
being obligated to contribute to the Company pursuant to Treasury Regulation Section 1.704-1(b)(2)(ii)(c) or Treasury Regulation Sections
1.704-2(g)(1) and 1.704-2(i); and

 

(b)
Each Member’s Capital Account shall be decreased by the amount of any of the items described in Treasury Regulation Sections 1.704-1(b)(2)(ii)(d)(4),
(5) and (6).

 

“Affiliate”
means with respect to any specified Person, any other Person that directly or indirectly controls, is under common control with, or is
controlled by, such specified Person and shall include without limitation any current or former limited partner, general partner, managing
member, manager, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or
more general partners or managing members of, or shares the same management with, such Person. As used in this definition, “control,”
including, its correlative meanings, “controlled by” and “under common control with,” shall mean possession of
power to direct or cause the direction of management or policies (whether through ownership of voting securities or partnership or other
ownership interests, by contract or otherwise).

 

“Ancillary
Agreements” means the Joint Venture Agreement and each of the attached agreements and transactions contemplated thereby.

 

“Applicable
Law” means and include all applicable statutes, enactments or acts of any legislative body or government authority of which
the Company is subject to, including all laws, ordinances, rules, bye-laws, regulations, notifications, guidelines, policies, directions
and orders of such legislative bodies of government authorities, and any amendments, modifications or enactments thereof.

 

“Available
Weekly Unit Vesting Amount” shall have the meaning set forth in Section 4.3(b).

 

“Board
Deadlock” means the Board is unable, after commercially reasonable efforts in good faith and at least two (2) duly held meetings
of the Board, to approve or disapprove any proposed action requiring approval of the Board under this Agreement that, as a result of
the deadlock with respect to such proposed action, has had or could reasonably be expected to have a material and adverse effect on the
(i) the achievement of the purposes of the Company, (ii) financial performance of the Company, (iii) operations of the Company, or (iv)
quality of services rendered by the Company.

 

“Capital
Account” means, with respect to any Member, the account maintained for such Member in accordance with the provisions of Section
4.5.

 

“Capital
Contribution” means, with respect to any Member, the aggregate amount of money and the initial Gross Asset Value of any property
(other than money) contributed to the Company pursuant to Article 4.

 

    	-1-

    	 

    

 

“Capital
Securities” means as to any Person that is a corporation, the authorized shares of such Person’s capital securities,
including all classes of common, preferred, voting and nonvoting capital securities, and, as to any Person that is not a corporation
or an individual, the ownership or membership interests in such Person, including, without limitation, the right to share in profits
and losses, the right to receive distributions of cash and property, and the right to receive allocations of items of income, gain, loss,
deduction and credit and similar items from such Person, whether or not such interests include voting or similar rights entitling the
holder thereof to exercise control over such Person.

 

“Certificate
of Formation” means the Certificate of Formation of the Company as originally filed with the Delaware Secretary of State on
March 10, 2020, and as amended from time to time.

 

“Change
of Control” shall mean (i) a merger or consolidation with a Person or Persons that are not directly or indirectly Affiliates
of the Company and in which the Company is a constituent party, except any such merger or consolidation in which the equity ownership
interests of the Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or
exchanged for shares of equity securities that represent, immediately following such merger or consolidation, at least a majority, by
voting power, of the equity ownership of the surviving or resulting entity (or the ultimate parent entity of such surviving or resulting
entity), or (ii) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions,
by the Company of all or substantially all the assets of the Company to Persons that are not directly or indirectly Affiliates of the
Company.

 

“Code”
means the U.S. Internal Revenue Code of 1986, as amended.

 

“Confidential
Information” means, without limitation, this Agreement, the Ancillary Agreements, Intellectual Property, any proprietary information,
software programs, plans, processes, policies, drawings, specifications, system and user documentation, correspondences, prototypes,
trade secrets, know how, design, invention, techniques, business methods, personal or sensitive data of employees, agents, consultants,
officers, directors, managers, customers or prospective customers or any other person which might reasonably be presumed to be confidential
in nature, financial information, technical information, sales and marketing plans or other business plans; whether recorded, written,
stored or transmitted in any form or medium by one disclosing party to a receiving party.

 

“Covered
Person” means (a) each Member and each officer, partner, director, stockholder, member, partner, representative or agent of
such Member, (b) the Tax Matters Partner, (c) any officer or employee of the Company, (d) any agent of the Company that the Board has
elected, in its discretion, to designate as a Covered Person, or (e) each Person who is or was serving at the request of the Company
as a director, manager, officer, member, partner, trustee, employee or other agent of another Person, including of any Subsidiary of
the Company.

 

“Fiscal
Period” means a calendar year or any portion thereof for which the Company is required to make allocations or distributions
pursuant to Article 5.

 

“Fiscal
Year” means a calendar year.

 

“Force
Majeure” means the occurrence of any event (a) not within the reasonable control of a party, (b) which could not have been
reasonably avoided by the party and (c) which materially interferes with the ability of a party to perform its obligations under this
Agreement, including without limitation, any natural calamities, acts of God, war, pandemic, civil unrest, labor shortages or disputes,
terrorist events or changes in Applicable Law.

 

“FTE”
shall have the meaning set forth in Section 4.3(a)(ii).

 

    	-2-

    	 

    

 

“Governmental
Authority” means any foreign or domestic, federal, state or local governmental, regulatory or administrative entity, authority,
commission, department, body, unit, tribunal, court or agency, including any political subdivision thereof.

 

“Gross
Asset Value” means, with respect to any asset, such asset’s adjusted basis for federal income tax purposes, except as
follows:

 

(a)
the initial Gross Asset Value of any asset contributed by a Member to the Company shall be the gross fair market value of such asset,
as agreed to by the contributing Member and the Board;

 

(b)
the Gross Asset Value of all Company assets shall be adjusted to equal their respective gross fair market values, as determined by the
Board, as of the following times: (i) the acquisition of an additional interest in the Company by any new or existing Member in exchange
for more than a de minimis Capital Contribution; (ii) the distribution by the Company to a Member of more than a de minimis
amount of Company assets as consideration for an interest in the Company; and (iii) the liquidation of the Company within the meaning
of Treasury Regulation Section 1.704-l(b)(2)(ii)(g) other than a constructive termination of the Company pursuant to Section 708(b)(1)(B)
of the Code; provided, however, that adjustments pursuant to clauses (i) and (ii) of this sentence shall be made only if
the Board reasonably determines such adjustments are necessary or appropriate to reflect the relative economic interests of the Members
in the Company.

 

(c)
the Gross Asset Value of any Company asset distributed to any Member shall be adjusted to equal the gross fair market value of such asset
on the date of distribution, as determined by the Member receiving such distribution and the Board.

 

“Hurdle
Amount” means, with respect to the Provider, initially the amount which is equal to the amount that would be received by all
Members if, immediately after the Units are issued to the Provider Member, the Company sold all of its assets for cash equal to their
fair market value, paid all of its liabilities (limited in the case of a nonrecourse liability to the fair market value of Company assets
securing such liability) and liquidated, with the Company distributing any remaining cash to the Members in accordance with Section
5.6. The Hurdle Amount with respect to the Provider shall be reduced (but not below zero) by the amount of any distributions to INVO
and increased by any additional Capital Contributions made by INVO, in each case, after the issuance of Units to the Provider. The Hurdle
Amount is intended to cause the Provider’s Units to qualify as “profits interests” within the meaning of Revenue Procedures
93-27 and 2001-43, and shall be interpreted and applied consistently therewith. The Hurdle Amount with respect to each Provider Unit
may be adjusted by the Board to the extent the Board determine in good faith such adjustment is necessary for such Provider Units to
constitute a “profits interests” within the meaning of Revenue Procedures 93-27 and 2001-43 or to reflect or preserve the
relative economic interests of the parties as intended hereunder.

 

“Intellectual
Property” means, without limitation, registered and unregistered trademarks, registered and unregistered service marks, trade
names, business names, trade dress, get-ups, logos, patents, registered and unregistered design rights, copyrights, database rights,
domain names and URLs, and all other similar rights in any part of the world (including in know-how) including, where such rights are
obtained or enhanced by registration, any registration of such rights and applications and rights to apply for such registrations in
and to the INVO Technologies, of INVO Bioscience and INVO.

 

“Intellectual
Property Agreements” means those certain (i) Intellectual Property License Agreement, dated as of the Effective Date, between
Bloom INVO LLC, a Delaware limited liability company and INVO Bioscience, Inc., (ii) Intellectual Property License Agreement, dated as
of the Effective Date, between Bloom Fertility, LLC, a Georgia limited liability company and Bloom INVO LLC, a Delaware limited liability
company, and (iii) Intellectual Property License Agreement, dated as of the Effective Date, between INVO Bioscience, Inc., a Nevada corporation,
and Bio X Cell, Inc., a Massachusetts corporation and Bloom INVO LLC, a Delaware limited liability company.

 

    	-3-

    	 

    

 

“INVO
Contribution” shall have the meaning set forth in Section 4.2.

 

“Liquidation”
means any voluntary or involuntary liquidation, dissolution or winding up of the Company, other than any dissolution, liquidation or
winding up in connection with a reincorporation of the Company in another jurisdiction.

 

“Member”
means each of the Persons who executes a counterpart of this Agreement as a Member, and includes any Person admitted as an additional
Member or a substitute Member pursuant to the provisions of this Agreement, in such Person’s capacity as a member of the Company.

 

“Membership
Rights” means all legal and beneficial ownership interests in, and rights and duties as a Member of, the Company, including,
without limitation, the right to share in Profits and Losses, the right to receive distributions of cash and other property from the
Company, and the right to receive allocations of items of income, gain, loss, deduction and credit and similar items from the Company.

 

“Minimum
Provider Commitment” shall have the meaning set forth in Section 4.3(b).

 

“Ordinary
Course of Business” means (a) actions taken in the Ordinary Course of Business of a Person consistent with past custom and
practice (including with respect to quantity, quality and frequency) of such Person; (b) actions taken that are similar in nature to
actions customarily taken in the ordinary course of the normal day-to-day operations of other Persons that are in the industry in which
the relevant Person and its Subsidiaries do business; or (c) actions taken that are consistent with such Person’s and/or operating
plan which are approved by the Board.

 

“Partnership
Audit Rules” means the provisions of Subchapter C of Chapter 63 of Subtitle A of the Code, as amended by the Bipartisan Budget
Act of 2015, P.L. 114-74 (together with any subsequent amendments thereto, Treasury Regulations promulgated thereunder, published administrative
interpretations thereof, and similar state and local laws).

 

“Per
Unit Pro Rata Basis” means, in reference to Units, divided among the Units equally on a per Unit pro rata basis. For
purposes of this definition, references to Units shall include both vested and unvested Units.

 

“Person”
includes any individual, corporation, association, partnership (general or limited), joint venture, trust, estate, limited liability
company, governmental body or agency or other legal entity or organization.

 

“Physician
Employees” shall have the meaning set forth in the JV Agreement.

 

“Physician
Owners” means those physicians who have an equity interest in Provider.

 

“Physician
Employment Agreements” shall have the meaning set forth in the JV Agreement.

 

“Profits”
and “Losses” means, for each Fiscal Period, an amount equal to the Company’s taxable income or loss for such
Fiscal Period, determined in accordance with Section 703(a) of the Code (but including in taxable income or loss, for this purpose, all
items of income, gain, loss, deduction or credit required to be stated separately pursuant to Section 703(a)(1) of the Code), with the
following adjustments:

 

    	-4-

    	 

    

 

(a)
any income of the Company exempt from federal income tax and not otherwise taken into account in computing Profits or Losses pursuant
to this definition shall be added to such taxable income or loss;

 

(b)
any expenditures of the Company described in Section 705(a)(2)(B) of the Code (or treated as expenditures described in Section 705(a)(2)(B)
of the Code pursuant to Treasury Regulation Section 1.704-1(b)(2)(iv)(i)) and not otherwise taken into account in computing Profits or
Losses pursuant to this definition shall be subtracted from such taxable income or loss;

 

(c)
in the event the Gross Asset Value of any Company asset is adjusted in accordance with paragraph (b) or paragraph (c) of the definition
of “Gross Asset Value” above, the amount of such adjustment shall be taken into account as gain or loss from the disposition
of such asset for purposes of computing Profits or Losses;

 

(d)
in lieu of the depreciation, amortization and other cost recovery deductions taken into account in computing the Company’s taxable
income or loss, there shall be taken into account depreciation as computed on the Company’s books and records for accounting purposes;

 

(e)
gain or loss resulting from any disposition of any asset of the Company with respect to which gain or loss is recognized for federal
income tax purposes shall be computed by reference to the Gross Asset Value of the asset disposed of, notwithstanding that the adjusted
tax basis of such asset differs from its Gross Asset Value; and

 

(f)
any items that are specially allocated pursuant to Section 5.1(b) shall not be taken into account in computing Profits and Losses.

 

“Provider
Requirements” shall have the meaning set forth in Section 4.2.

 

“Provider
Vesting Period” shall have the meaning set forth in Section 4.3(a)(ii).

 

“Securities
Act” means the Securities Act of 1933, as amended, or any successor statute.

 

“Subsidiary(ies)”
means any Person the majority of the Capital Securities of which, directly, or indirectly through or one or more Persons, (a) such Person
has the right to acquire or (b) is owned or controlled by such Person. As used in this definition, “control,” including,
its correlative meanings, “controlled by” and “under common control with,” shall mean possession, directly or
indirectly, of power to direct or cause the direction of management or policies (whether through ownership of Capital Securities, by
contract or otherwise).

 

“Treasury
Regulation” means and refers to a provision of the temporary or final regulations promulgated by the United States Department
of the Treasury pursuant to the Code.

 

“Units”
means, collectively the class of Membership Rights created hereunder.

 

“Vested
Units” shall have the meaning set forth in Section 4.3.

 

    	-5-

    	 

    

 

Exhibit
B

 

Members

 

 

	Name
    of Member	 	Number
    of Units	 	Capital
    Contribution
	Bloom
    Fertility, LLC 

    987 Canton Street, Bldg. 14

    Roswell, GA, 30075

    Attention: Sue Ellen Carpenter, M.D. 

    Email: sekcarpenter@mindspring.com	 	1,200
    Units, subject to vesting.	 	Provider
    Services equivalent to or greater than the Minimum Provider Commitment for the Provider Vesting Period, consistent with Section
    4.3(b).
	 	 	 	 	 
	INVO
    Centers, LLC

    5582
    Broadcast Court

    Sarasota,
    FL 34240

    Email:
    legal@invobio.com
	 	800
    Units, subject to vesting.	 	Up
    to $800,000, as mutually agreed to by the Parties in the Business Plan to be contributed in increments of Fifty Thousand Dollars
    ($50,000), consistent with Section 4.3(b). 

 

    	-6-

    	 

    

 

Exhibit
C

 

Member
Obligations

 

The
obligations below shall take effect following the execution of, and pursuant to the terms and conditions of, the Joint Venture Agreement
and any applicable Ancillary Agreement, and shall be subject to the terms and provisions of this Agreement and the direction of the Board
and the Members (provided such direction is in accordance with Applicable Law).

 

Provider:

 

1.
Provide clinical practice expertise and oversight to the INVO Clinic.

 

2.
Perform all recruitment functions of the Provider and collaborate with INVO on Company recruitment functions.

 

3.
Manage the INVO Clinic’s day-to-day medical practice and patient support operations.

 

4.
Collaborate with INVO on the INVO Clinic’s buildout and launch, on establishing standard operating procedures, on managing marketing,
compliance and accreditation tasks, and on providing and/or procuring all necessary training.

 

INVO:

 

1.
Provide access to, and be the exclusive supplier to the Company of, the INVO Technologies, including subsequent new product generations,
in accordance with that certain Distribution Agreement, dated November 12, 2018, by and among Ferring International Center S.A., INVO
Bioscience and Bio X Cell, Inc., as amended.

 

2.
Provide necessary product documentation for product registrations of the Company.

 

3.
Collaborate with Provider on Company recruitment functions.

 

4.
Manage the INVO Clinic’s day-to-day laboratory operations.

 

5.
Collaborate with Provider on the INVO Clinic’s buildout and launch, on establishing standard operating procedures, on managing
marketing, compliance and accreditation tasks, and on providing and/or procuring all necessary training.

 

Exhibit
D

 

Member
Acknowledgements, Representations and Warranties Related to Company Securities

 

1.
Investment Intent. Such Member is (i) an “accredited investor” as defined in Regulation D of the Securities Act, and
(ii) acquiring the Units to be purchased or otherwise acquired by such Member pursuant to Article 4 for investment only and not
with a view to the distribution thereof. Such Member hereby agrees that it, she or he will not transfer the Units in a manner that will
violate Securities Laws.

 

2.
Investment Risk. Such Member represents that it, she or he is in a financial position to hold the Units for an indefinite period
of time and able to bear the economic risk and withstand a complete loss of its, her or his investment in the Units.

 

3.
Authorization. The execution, delivery and performance by such Member of this Agreement has been duly authorized by all necessary
or appropriate action.

 

    	 

     

    

 

4.
Enforceability. The execution and delivery by such Member of this Agreement will result in legally binding obligations of such
Member enforceable against such Member in accordance with the respective terms and provisions hereof and thereof, except as may be limited
by bankruptcy, insolvency, reorganization, moratorium and other similar laws of general applicability relating to or affecting creditors’
rights or general equity principles (regardless of whether considered at law or in equity).

 

5.
Exemption. Such Member understands that the Units are not registered under any Securities Law on the grounds that the Company
intends the sale and the issuance of securities hereunder to be exempt from registration under the Securities Act pursuant to Regulation
D thereof or other exemptions available thereunder, and that the Company’s reliance on such exemption is predicated on the Members’
representations set forth herein.

 

6.
Experience. Such Member is experienced in evaluating and investing in companies such as the Company, or is familiar with the risks
associated with the business and operations of the Company, and has such knowledge and experience in financial and business matters as
to be capable of evaluating the merits and risks of its investment.

 

7.
Restrictions on Resale. Such Member understands that the Units may not be sold, transferred or otherwise disposed of without registration
under applicable Securities Laws or an exemption therefrom, and that in the absence of an effective registration statement covering the
Units or an available exemption from registration under the applicable Securities Laws, the Units must be held indefinitely. Such Member
understands that any certificates representing the Units may bear a restrictive legend to this effect.

 

8.
No Legal Actions. No legal action or suit against such Member, or to which such Member is a party, is pending or, to the knowledge
of such Member, threatened, which seeks to delay or prevent the consummation of any of the transactions contemplated by this Agreement.

 

9.
Separate Counsel. Each Member has had the opportunity to seek the advice of counsel and other personal advisors and acknowledges
that neither the Company nor any of its Affiliates has provided such Member with any advice regarding the tax, economic or other impacts
to such Member of the arrangements contemplated hereby.

 

10.
No Conflicts. Such Member is not party to, subject to or bound by any agreement or any judgment, order, writ, prohibition, injunction,
decree, award or other requirement of any governmental entity that would prevent the execution or delivery of this Agreement. The execution
and delivery by such Member of this Agreement does not, and the performance of this Agreement will not, (A) conflict with, result in
a breach of, constitute (with or without due notice or lapse of time or both) a default under, or require any notice, consent or waiver
under, any material contract, instrument or other agreement to which such Member is a party (either with the Company or with another
Person) or to which such Member may be bound or subject, (B) violate any fiduciary or confidential relationship or (C) conflict with
or violate the provisions of any Applicable Laws or any order of any governmental entity. No Party shall enter into any agreements or
arrangements of any kind with any Person with respect to any Units or other equity securities of the Company that would prohibit such
Party from complying with the applicable provisions of this Agreement (whether or not such agreements or arrangements are with other
Parties or with Persons that are not a party to this Agreement).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]